View Filing Data

Document and Entity Information Document - shares	9 Months Ended
Document and Entity Information Document - shares	Sep. 30, 2012	Nov. 13, 2012
Document Information [Line Items]
Entity Registrant Name	NeoStem, Inc.
Entity Central Index Key	0000320017
Current Fiscal Year End Date	--12-31
Entity Filer Category	Smaller Reporting Company
Document Type	10-Q
Document Period End Date	Sep. 30, 2012
Document Fiscal Year Focus	2012
Document Fiscal Period Focus	Q3
Amendment Flag	false
Entity Common Stock, Shares Outstanding		159,414,582

Consolidated Balance Sheets - USD ($)	Sep. 30, 2012	Dec. 31, 2011
Current Assets
Cash and cash equivalents	$ 5,390,611	$ 3,935,160
Accounts receivable trade, net of allowance for doubtful accounts of $442,302 and $187,600, respectively	1,794,579	1,010,475
Inventory	448,045	647,745
Prepaids and other current assets	3,228,775	649,739
Assets related to discontinued operations	37,024,245	32,367,217
Total current assets	47,886,255	38,610,336
Property, plant and equipment, net	11,067,570	11,616,053
Goodwill	11,117,770	11,117,770
Intangible assets, net	14,632,130	15,086,038
Other assets	932,474	3,326,938
Assets related to discontinued operations	43,169,861	75,570,645
Assets, Total	128,806,060	155,327,780
Current Liabilities
Accounts payable	2,570,879	2,287,201
Accrued liabilities	1,385,510	1,090,176
Notes payable	135,222	148,062
Mortgages payable	3,493,708	3,635,061
Unearned revenues	778,088	1,121,134
Other liabilities	2,728,000	0
Liabilities related to discontinued operations	39,343,867	28,165,010
Total current liabilities	50,435,274	36,446,644
Long-term Liabilities
Deferred income taxes	3,774,655	3,774,655
Unearned revenues	143,734	169,198
Notes payable	48,317	0
Derivative liabilities	427,553	474,463
Acquisition-related contingent consideration	3,130,000	3,130,000
Other long-term liabilities	139,276	0
Liabilities related to discontinued operations	14,279,651	26,388,976
Total long-term liabilities	21,943,186	33,937,292
Commitments and Contingencies
Redeemable Securities
Convertible Redeemable Series E Preferred Stock; 10,582,011 shares designated, liquidation value $1.00 per share; issued and outstanding 3,135,411 and 6,662,748 shares, at September 30, 2012 and December 31, 2011, respectively	2,721,132	4,811,326
Shareholders' Equity
Preferred stock; authorized, 20,000,000 shares Series B convertible redeemable preferred stock liquidation value, 1 share of common stock, $.01 par value; 825,000 shares designated; issued and outstanding, 10,000 shares at September 30, 2012 and December 31, 2011	100	100
Common stock, $.001 par value, authorized 500,000,000 shares; issued and outstanding, 155,141,086 and 109,329,587 shares, at September 30, 2012 and December 31, 2011, respectively	155,141	109,330
Additional paid-in capital	225,528,652	200,858,638
Accumulated deficit	(181,622,667)	(143,094,854)
Accumulated other comprehensive income	4,148,767	4,152,343
Total NeoStem, Inc. shareholders' equity	48,209,993	62,025,557
Noncontrolling interests	5,496,475	18,106,961
Total equity	53,706,468	80,132,518
Liabilities and Equity, Total	$ 128,806,060	$ 155,327,780

Consolidated Balance Sheets (Parenthetical) - USD ($)	Sep. 30, 2012	Dec. 31, 2011
Accounts receivable trade, net of allowance for doubtful accounts	$ 442,302	$ 187,600
Convertible Redeemable Series E Preferred Stock, shares designated	10,582,011	10,582,011
Convertible Redeemable Series E Preferred Stock, liquidation value per share	$ 1.00	$ 1.00
Convertible Redeemable Series E Preferred Stock, issued	3,135,411	6,662,748
Convertible Redeemable Series E Preferred Stock, outstanding	3,135,411	6,662,748
Preferred Stock, authorized	20,000,000	20,000,000
Series B convertible redeemable preferred stock liquidation value, 1 share of common stock, par value	1	1
Preferred stock, par value	$ 0.01	$ 0.01
Preferred stock, shares designated	825,000	825,000
Preferred stock, issued	10,000	10,000
Preferred stock, outstanding	10,000	10,000
Common Stock, Par Value	$ 0.001	$ 0.001
Common Stock, authorized	500,000,000	500,000,000
Common Stock, Shares, Issued	155,141,086	109,329,587
Common stock, outstanding	155,141,086	109,329,587

Consolidated Statements of Operations - USD ($)	3 Months Ended		9 Months Ended
Consolidated Statements of Operations - USD ($)	Sep. 30, 2012	Sep. 30, 2011	Sep. 30, 2012	Sep. 30, 2011
Revenues	$ 4,433,961	$ 2,177,013	$ 11,578,783	$ 5,836,978
Cost of revenues	3,747,490	1,891,334	9,439,185	5,336,079
Gross profit	686,471	285,679	2,139,598	500,899
Research and development	2,828,210	1,540,441	7,490,002	5,656,875
Selling, general, and administrative	5,947,264	5,975,688	17,092,493	21,293,386
Operating Expenses	8,775,474	7,516,129	24,582,495	26,950,261
Operating loss	(8,089,003)	(7,230,450)	(22,442,897)	(26,449,362)
Other income (expense):
Other income, net	(74,881)	1,292,911	36,924	1,572,807
Interest expense	(384,168)	(632,837)	(1,359,187)	(2,060,068)
Nonoperating Income (Expense), Total	(459,049)	660,074	(1,322,263)	(487,261)
Net loss from continuing operations	(8,548,052)	(6,570,376)	(23,765,160)	(26,936,623)
Loss from discontinued operations - net	152,095	(758,088)	(27,260,584)	(792,113)
Net loss	(8,395,957)	(7,328,464)	(51,025,744)	(27,728,736)
Less - loss from continuing operations attributable to noncontrolling interests	(59,572)	(35,222)	(248,294)	(237,127)
Less - loss (income) from discontinued operations attributable to noncontrolling interests	74,524	53,193	(12,513,069)	796,206
Net loss attributable to NeoStem, Inc.	(8,410,909)	(7,346,435)	(38,264,381)	(28,287,815)
Warrant inducements	(1,012,819)	0	(1,012,819)	0
Preferred dividends	(67,197)	(150,655)	(263,432)	(508,070)
Net loss attributable to NeoStem, Inc. common shareholders	(9,490,925)	(7,497,090)	(39,540,632)	(28,795,885)
Amounts Attributable to NeoStem, Inc. common shareholders:
Loss from continuing operations	(8,488,480)	(6,535,154)	(23,516,866)	(26,699,496)
Loss from discontinued operations - net of taxes	77,571	(811,281)	(14,747,515)	(1,588,319)
Warrant inducements	(1,012,819)	0	(1,012,819)	0
Preferred dividends	(67,197)	(150,655)	(263,432)	(508,070)
Net loss attributable to NeoStem, Inc. common shareholders	$ (9,490,925)	$ (7,497,090)	$ (39,540,632)	$ (28,795,885)
Basic and diluted (loss) per share attributable to:
Continuing operations	$ (0.06)	$ (0.07)	$ (0.18)	$ (0.32)
Discontinued operations	0.00	(0.01)	(0.11)	(0.02)
NeoStem, Inc. common shareholders	$ (0.06)	$ (0.08)	$ (0.30)	$ (0.35)
Weighted average common shares outstanding	148,197,077	94,102,589	131,533,057	82,775,215

Consolidated Statements of Comprehensive income - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2012	Sep. 30, 2011	Sep. 30, 2012	Sep. 30, 2011
Net loss	$ (8,395,957)	$ (7,328,464)	$ (51,025,744)	$ (27,728,736)
Other comprehensive income (loss):
Foreign currency translation elimination on discontinued operations	0	0	(169,993)	0
Foreign currency translation	(50,128)	2,134,363	317,294	2,222,569
Total other comprehensive (loss) income	(50,128)	2,134,363	147,301	2,222,569
Comprehensive loss	(8,446,085)	(5,194,101)	(50,878,443)	(25,506,167)
Comprehensive (loss) income attributable to noncontrolling interests	(9,611)	(705,130)	(12,610,486)	1,609,135
Comprehensive net loss attributable to NeoStem, Inc. common shareholders	$ (8,436,474)	$ (4,488,971)	$ (38,267,957)	$ (27,115,302)

- Definition

The change in equity [net assets] of a business enterprise during a period from transactions and other events and circumstances from non-owner sources which are attributable to the reporting entity. It includes all changes in equity during a period except those resulting from investments by owners and distributions to owners, but excludes any and all transactions which are directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Research Bulletin (ARB)
-Number 51
-Paragraph 8, 9, 10, 11, 12, 13, 14
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Research Bulletin (ARB)
-Number 51
-Paragraph 30
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Research Bulletin (ARB)
-Number 51
-Paragraph A5
-Appendix A

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=6920043&loc=d3e557-108580

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Net Income
-URI http://asc.fasb.org/extlink&oid=6518256

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Other Comprehensive Income
-URI http://asc.fasb.org/extlink&oid=6519514

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6920043&loc=d3e540-108580

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Comprehensive Income
-URI http://asc.fasb.org/extlink&oid=6508144

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Research Bulletin (ARB)
-Number 51
-Paragraph 38
-Subparagraph c(3)
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

- Definition

The change in equity [net assets] of a business enterprise during a period from transactions and other events and circumstances from non-owner sources which are attributable to noncontrolling interests, if any. It includes all changes in equity during a period except those resulting from investments by owners and distributions to owners, which are directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent.

+ References + Details

- Definition

The change in equity [net assets] of a business enterprise during a period from transactions and other events and circumstances from non-owner sources which are attributable to the economic entity, including both controlling (parent) and noncontrolling interests. It includes all changes in equity during a period except those resulting from investments by owners and distributions to owners, including any and all transactions which are directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent.

+ References + Details

- Definition

Change in the balance sheet adjustment that results from the process of translating subsidiary financial statements and foreign equity investments into functional currency of the reporting entity for the period being reported, net of tax. If an entity's functional currency is a foreign currency, translation adjustments result from the process of translating that entity's financial statements into the reporting currency. Includes gain (loss) on foreign currency forward exchange contracts. Includes foreign currency transactions designated as hedges of net investment in a foreign entity and intercompany foreign currency transactions that are of a long-term nature, when the entities to the transaction are consolidated, combined, or accounted for by the equity method in the reporting enterprise's financial statements. Includes the gain (loss) on a derivative instrument or nonderivative financial instrument that may give rise to a foreign currency transaction gain (loss) and that have been designated and have qualified as hedging instruments for hedges of the foreign currency exposure of a net investment in a foreign operation.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 133
-Paragraph 45
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 52
-Paragraph 13, 20, 31
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 130
-Paragraph 17
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=6920043&loc=d3e637-108580

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 830
-SubTopic 30
-Section 45
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=6915805&loc=d3e32022-110900

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 830
-SubTopic 30
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 13
-URI http://asc.fasb.org/extlink&oid=6920043&loc=d3e653-108580

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 830
-SubTopic 30
-Section 45
-Paragraph 18
-URI http://asc.fasb.org/extlink&oid=6915805&loc=d3e32157-110900

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 830
-SubTopic 30
-Section 45
-Paragraph 20
-URI http://asc.fasb.org/extlink&oid=6915805&loc=d3e32211-110900

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 55
-Paragraph 2
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6920433&loc=d3e998-108581

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Research Bulletin (ARB)
-Number 51
-Paragraph 38
-Subparagraph c(3)
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

- Definition

This element represents Other Comprehensive Income or Loss, Net of Tax, for the period. Includes deferred gains or losses on qualifying hedges, unrealized holding gains or losses on available-for-sale securities, minimum pension liability, and cumulative translation adjustment. While for technical reasons this element has no balance attribute, the default assumption is a credit balance consistent with its label.

+ References

+ Details

- Definition

The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Research Bulletin (ARB)
-Number 51
-Paragraph 29
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Research Bulletin (ARB)
-Number 51
-Paragraph 38
-Subparagraph a
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Research Bulletin (ARB)
-Number 51
-Paragraph A1, A4, A5
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Research Bulletin (ARB)
-Number 51
-Paragraph 5
-Subparagraph b
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 55
-Paragraph 4K
-URI http://asc.fasb.org/extlink&oid=6922042&loc=SL4591552-111686

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 45
-Paragraph 19
-URI http://asc.fasb.org/extlink&oid=6921628&loc=SL4569616-111683

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 55
-Paragraph 4J
-URI http://asc.fasb.org/extlink&oid=6922042&loc=SL4591551-111686

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 1A
-Subparagraph (a),(c)
-URI http://asc.fasb.org/extlink&oid=6921930&loc=SL4573702-111684

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Research Bulletin (ARB)
-Number 51
-Paragraph 38
-Subparagraph c(1)
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Consolidated Statements of Equity - 9 months ended Sep. 30, 2012 - USD ($)	Total	Series B Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Accumulated Other Comprehensive Income (Loss) [Member]	Accumulated Deficit [Member]	Total NeoStem, Inc. Shareholders' Equity [Member]	Non-Controlling Interest in Subsidiary [Member]
Beginning Balance (in shares) at Dec. 31, 2011		10,000	109,329,587
Beginning Balance at Dec. 31, 2011	$ 80,132,518	$ 100	$ 109,330	$ 200,858,638	$ 4,152,343	$ (143,094,854)	$ 62,025,557	$ 18,106,961
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss	(51,025,744)	0	0	0	0	(38,264,381)	(38,264,381)	(12,761,363)
Foreign currency translation	147,301	$ 0	$ 0	0	(3,576)	0	(3,576)	150,877
Share-based compensation (in shares)		0	2,634,028
Share-based compensation	5,471,166	$ 0	$ 2,634	5,468,532	0	0	5,471,166	0
Proceeds from issuance of common stock (in shares)		0	28,765,623
Proceeds from issuance of common stock	12,160,227	$ 0	$ 28,766	12,131,461	0	0	12,160,227	0
Proceeds from warrant exercises (in shares)			10,160,521
Proceeds from warrant exercises	5,925,931		$ 10,160	5,915,771			5,925,931
Repayment of Series E Preferred Principal and Dividends (in shares)		0	2,792,375
Repayment of Series E Preferred Principal and Dividends	938,785	$ 0	$ 2,792	1,199,425	0	(263,432)	938,785	0
Warrant inducements (in shares)			1,458,952
Warrant inducements	(43,716)		$ 1,459	(45,175)		0	(43,716)
Ending Balance (in shares) at Sep. 30, 2012		10,000	155,141,086
Ending Balance at Sep. 30, 2012	$ 53,706,468	$ 100	$ 155,141	$ 225,528,652	$ 4,148,767	$ (181,622,667)	$ 48,209,993	$ 5,496,475

Consolidated Statements of Cash Flows - USD ($)	9 Months Ended
Consolidated Statements of Cash Flows - USD ($)	Sep. 30, 2012	Sep. 30, 2011
Cash flows from operating activities:
Net loss	$ (51,025,744)	$ (27,728,736)
Loss from discontinued operations	27,260,584	792,113
Adjustments to reconcile net loss to net cash used in operating activities:
Common stock, stock options and warrants issued as payment for compensation, services rendered and interest expense	5,471,166	8,164,814
Depreciation and amortization	1,160,596	1,221,346
Amortization of preferred stock discount and issuance cost	1,195,217	1,903,703
Changes in fair value of derivative liability	(46,910)	(1,661,049)
Write off of acquired in-process research and development	0	1,150,000
Loss on disposal of assets	12,964	0
Contributions paid with common stock	0	607,363
Bad debt expense (recovery)	328,003	59,538
Changes in operating assets and liabilities, net of the effect of acquisitions:
Prepaid expenses and other current assets	4,337	(223,527)
Accounts receivable	(1,112,107)	(944,206)
Inventory	199,700	779,043
Unearned revenues	(368,510)	(159,900)
Other assets	(187,123)	125,489
Accounts payable, accrued expenses and other current liabilities	711,997	(46,418)
Net cash used in operating activities - continuing operations	(16,395,830)	(15,960,427)
Net cash provided by (used in) operating activities - discontinued operations	12,168,199	(1,562,004)
Net cash used in operating activities	(4,227,631)	(17,522,431)
Cash flows from investing activities:
Cash received in acquisitions	0	227,942
Cash received in divestiture	2,728,000	0
Change in restricted cash used as collateral for notes payable	0	(752)
Acquisition of property and equipment	(197,577)	(506,783)
Net cash used in investing activities - continuing operations	2,530,423	(279,593)
Net cash used in investing activities - discontinued operations	(5,218,531)	(2,848,309)
Net cash used in investing activities	(2,688,108)	(3,127,902)
Cash flows from financing activities:
Net proceeds from exercise of options	0	7,100
Net proceeds from exercise of warrants	5,925,931	0
Net proceeds from issuance of capital stock	12,160,227	21,167,682
Repayment of mortgage loan	(141,353)	(109,492)
Proceeds from notes payable	223,433	149,766
Repayment of notes payable	(187,956)	(132,891)
Repayment of debt to related party	0	(3,000,000)
Repayment of preferred stock	(2,258,852)	(175,000)
Payment of dividend for preferred stock	(56,850)	0
Payment for warrant inducement	(43,716)	0
Net cash provided by financing activities - continuing operations	15,620,864	17,907,165
Net cash provided by financing activities - discontinued operations	(5,198,330)	(1,390,641)
Net cash provided by financing activities	10,422,534	16,516,524
Impact of changes of foreign exchange rates	(72,136)	234,756
Net increase/(decrease) in cash and cash equivalents	3,434,659	(3,899,053)
Cash and cash equivalents at beginning of period	12,745,432	15,612,391
Cash and cash equivalents at end of period	16,180,091	11,713,338
Less cash and cash equivalents of discontinued operations at end of period	10,789,480	1,548,351
Cash and cash equivalents of continuing operations at end of period	5,390,611	10,164,987
Cash paid during the period for:
Interest	1,655,600	1,238,400
Taxes	1,841,400	1,463,100
Supplemental Schedule of non-cash investing activities:
Capitalized interest	154,700	235,700
Supplemental schedule of non-cash financing activities
Common stock and warrants issued with the acquisition of PCT	0	17,200,000
Common stock issued pursuant to the redemption of Convertible Redeemable Series E 7% Preferred Stock	1,026,600	2,785,400
Common stock issued in payment of dividends for the Convertible Redeemable Series E 7% Preferred Stock	175,700	622,500
Dividend to related party reinvested as loan payable	$ 0	$ 11,726,100

The Business

9 Months Ended

Sep. 30, 2012

The Business [Abstract]

The Business [Text Block]

The Business

Overview

NeoStem, Inc. (“NeoStem” or the “Company”) was incorporated under the laws of the State of Delaware in September 1980 under the name Fidelity Medical Services, Inc. The Company’s corporate headquarters are located at 420 Lexington Avenue, Suite 350, New York, NY 10170. The Company’s telephone number is (212) 584-4180 and its website address is www.neostem.com.

The Company is emerging as a technology and market leading company in the fast developing cell therapy industry. The Company's multifaceted business strategy combines a state-of-the-art contract development and manufacturing organization (CDMO) with a medically important cell therapy product development program enabling short-term and long-term revenue growth opportunities. The Company's service business and pipeline of proprietary cell therapy products work in concert, giving the Company a competitive advantage that it believes is unique to the biotechnology and pharmaceutical industries. Supported by an experienced scientific and business management team and a strategic and growing patent and patent pending (IP) portfolio, the Company is well positioned to succeed.

As a leading cell therapy Company, we have a pipeline of proprietary products, including stem cell therapies for cardiovascular disease and regenerative medicine as well as a T cell therapy for autoimmune disorders. Through its GMP facilities, NeoStem further supports the cell therapy community’s efforts to discover solutions for chronic disease by providing contract development and manufacturing expertise. In addition, NeoStem offers adult stem cell collection, processing and storage services in the U.S., enabling healthy individuals to donate and store their stem cells for personal therapeutic use.

In 2011, the Company operated its business in three reportable segments: (i) Cell Therapy — United States; (ii) Regenerative Medicine — China; and (iii) Pharmaceutical Manufacturing — China. In 2012, the Company began to exit its operations in China. Effective March 31, 2012, the Company no longer operated in the Regenerative Medicine – China reportable segment, which is now reported in discontinued operations (see Note 13). On June 18, 2012, the Company signed a definitive agreement to sell its 51% interest in Suzhou Erye, which represented the operations in our Pharmaceutical Manufacturing - China segment, and is also reported in discontinued operations (see Note 13). The Erye divestiture closed on November 13, 2012 (see Note 16). As a result, the Company currently operates in a single reporting segment - Cell Therapy, which will focus on CDMO and cell therapy development programs.

Basis of Presentation

The accompanying unaudited Consolidated Financial Statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“generally accepted accounting principles”) for interim financial information and with the instructions to Form 10-Q and Article 8 of Regulation S-X of the Securities and Exchange Commission for interim financial information. Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements. In the opinion of management, the accompanying Consolidated Financial Statements of the Company and its subsidiaries, which are unaudited, include all normal and recurring adjustments considered necessary to present fairly the Company’s financial position as of September 30, 2012 and the results of its operations and its cash flows for the periods presented. The unaudited consolidated financial statements herein should be read together with the historical consolidated financial statements of the Company for the years ended December 31, 2011 and 2010 included in our Annual Report on Form 10-K for the year ended December 31, 2011, as recast in our Current Report on Form 8-K filed with the SEC on August 15, 2012 to reflect our Pharmaceutical Manufacturing - China and Regenerative Medicine - China segments as discontinued operations. Operating results for the three and nine months ended September 30, 2012 are not necessarily indicative of the results that may be expected for the year ending December 31, 2012.

Use of Estimates

The preparation of financial statements in conformity with generally accepted accounting principles in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements. Estimates also affect the reported amounts of revenues and expenses during the reporting period. Accordingly, actual results could differ from those estimates.

Principles of Consolidation

The consolidated financial statements include the accounts of NeoStem, Inc. and its wholly owned and partially owned subsidiaries and affiliates as listed below:



Entity	Percentage of Ownership	Location
NeoStem, Inc.	Parent Company	United States of America
NeoStem Therapies, Inc.	100%	United States of America
Stem Cell Technologies, Inc.	100%	United States of America
Amorcyte, LLC	100%	United States of America
CBH Acquisition LLC	100%	United States of America
China Biopharmaceuticals Holdings, Inc. (CBH)	100% owned by CBH Acquisition LLC	United States of America
Suzhou Erye Pharmaceuticals Company Ltd. (1)	51% owned by CBH	People’s Republic of China
Progenitor Cell Therapy, LLC (PCT)	100%	United States of America
NeoStem Family Storage, LLC	100% owned by PCT	United States of America
Athelos Corporation	80.1% owned by PCT	United States of America
PCT Allendale, LLC	100% owned by PCT	United States of America

(1) Represents the operations of our former Pharmaceutical Manufacturing - China reporting segment, which was discontinued on June 18, 2012, and is currently reported in discontinued operations. The Erye divestiture closed on November 13, 2012 (see Note 16).

Summary of Significant Accounting Policies	9 Months Ended
Summary of Significant Accounting Policies	Sep. 30, 2012
Summary of Significant Accounting Policies [Abstract]
Summary of Significant Accounting Policies [Text Block]	Summary of Significant Accounting Policies In addition to the policies below, our significant accounting policies are described in Note 2 of the Notes to Consolidated Financial Statements included in our Annual Report on Form 10-K for the year ended December 31, 2011, as recast in our Current Report on Form 8-K filed with the SEC on August 15, 2012. There were no changes during the nine months ended September 30, 2012. Accounts Receivable Accounts receivable are carried at original invoice amount less an estimate made for doubtful accounts. The Company applies judgment in connection with establishing the allowance for doubtful accounts. Specifically, the Company analyzes the aging of accounts receivable balances, historical bad debts, customer concentration and credit-worthiness, current economic trends and changes in the Company’s customer payment terms. Significant changes in customer concentrations or payment terms, deterioration of customer credit-worthiness or weakening economic trends could have a significant impact on the collectability of the receivables and the Company’s operating results. If the financial condition of the Company’s customers were to deteriorate, resulting in an impairment of their ability to make payments, additional allowances may be required. Management regularly reviews the aging of receivables and changes in payment trends by its customers, and records a reserve when it believes collection of amounts due are at risk. Revenue Recognition Clinical Services: The Company recognizes revenue for its cell development and manufacturing services based on the terms of individual contracts. Revenues associated with cell development services which contain multiple stages that do not have stand-alone values and are dependent upon one another are recognized as revenue on a completed contract basis. Cell services and manufacturing services which have separate and distinct arrangements, and the Company is paid for time and materials or for fixed monthly amounts is recognized as revenue when efforts are expended or contractual terms have been met. Clinical Services Reimbursements: The Company separately charges the customers for the expenses associated with certain consumable resources (reimbursable expenses) that are specified in each clinical services contract. On a monthly basis, the Company bills customers for reimbursable expenses and immediately recognizes these billings as revenue, as the revenue is deemed earned as reimbursable expenses are incurred. For the three months ended September 30, 2012 and 2011, clinical services reimbursements were $0.9 million and $0.7 million, respectively. For the nine months ended September 30, 2012 and 2011, clinical services reimbursements were $2.9 million and $1.8 million, respectively. Processing and Storage Services: The Company recognizes revenue related to the collection and cryopreservation of cord blood and autologous adult stem cells when the cryopreservation process is completed which is approximately twenty-four hours after cells have been collected. Revenue related to advance payments of storage fees is recognized ratably over the period covered by the advance payments. New Accounting Pronouncements In July 2012, the FASB issued ASU 2012-02, “Intangibles - Goodwill and Other (Topic 350) - Testing Indefinite-Lived Intangible Assets for Impairment.” The guidance is intended to simplify impairment testing of indefinite-lived intangible assets such as In-Process Research and Development by first assessing qualitative factors to determine whether it is “more likely than not” that the fair value of an asset is less than its carrying amount as a basis for determining whether it is necessary to perform a quantitative impairment test. The more-likely-than-not threshold is defined as having a likelihood of more than 50%. This guidance is effective for annual and interim tests performed for fiscal years beginning after September 15, 2012. The adoption of this guidance is not expected to have a significant impact on the Company's financial position or results of operations.

Acquisitions

9 Months Ended

Sep. 30, 2012

Acquisitions [Abstract]

Acquisitions [Text Block]

Acquisitions

Amorcyte Acquisition

On October 17, 2011 (the “Closing Date”), Amo Acquisition Company I, Inc. (“Subco”), a newly-formed wholly-owned subsidiary of NeoStem, merged (the “Amorcyte Merger”) with and into Amorcyte, Inc., a Delaware corporation (“Amorcyte”), in accordance with the terms of the Agreement and Plan of Merger, dated as of July 13, 2011 (the “Amorcyte Merger Agreement”), among NeoStem, Amorcyte, Subco, and Amo Acquisition Company II, LLC (“Subco II”). As a result of the consummation of the Amorcyte Merger, Amorcyte is now a wholly-owned subsidiary of NeoStem. Amorcyte is a development stage cell therapy company focusing on novel treatments for cardiovascular disease.

The fair value of assets acquired and liabilities assumed on October 17, 2011 is as follows (in thousands):



Cash	$	92.9
Prepaid Expenses	178.2
In Process R&D	9,400.0
Goodwill	4,104.5
Accounts Payable & Accrued Liabilities	1,177.1
Deferred Tax Liability	3,774.7
Amount Due Related Party	340.4

The total cost of the acquisition has been allocated to the assets acquired and the liabilities assumed based upon their estimated fair values at the date of the acquisition. The Company completed its review of the final allocation and valuation during the second quarter of 2012 and there were no changes from our preliminary assessment.

- Definition

The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Emerging Issues Task Force (EITF)
-Number 88-16
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 141
-Paragraph 51, 52
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 141R
-Appendix F
-Paragraph F4
-Subparagraph e

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 141R
-Paragraph 67-73
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6911361&loc=d3e6927-128479

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6972119&loc=d3e1490-128463

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6911361&loc=d3e7008-128479

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6972119&loc=d3e1500-128463

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6910749&loc=d3e4926-128472

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6910749&loc=d3e4922-128472

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6911361&loc=d3e6996-128479

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=6972119&loc=d3e1524-128463

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6972119&loc=d3e1392-128463

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6911361&loc=d3e7000-128479

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6910749&loc=d3e4845-128472

Reference 16: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6910749&loc=d3e4934-128472

Reference 17: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=6972119&loc=d3e1497-128463

Reference 18: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6972119&loc=d3e1486-128463

Reference 19: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6972119&loc=d3e1383-128463

+ Details

Cash and Cash Equivalents	9 Months Ended
Cash and Cash Equivalents	Sep. 30, 2012
Cash and Cash Equivalents [Abstract]
Cash and Cash Equivalents [Text Block]	Cash and Cash Equivalents Cash and cash equivalents include short-term, highly liquid, investments with maturities of ninety days or less when purchased. As of September 30, 2012 and December 31, 2011, the Company had cash and cash equivalents of approximately $5.4 million and $3.9 million, respectively, including bank deposits of approximately $0.6 million and $0.8 million, respectively, covered by the Federal Deposit Insurance Corporation.

- Definition

The entire disclosure for cash and cash equivalent footnotes, which may include the types of deposits and money market instruments, applicable carrying amounts, restricted amounts and compensating balance arrangements. Cash and equivalents include: (1) currency on hand (2) demand deposits with banks or financial institutions (3) other kinds of accounts that have the general characteristics of demand deposits (4) short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Generally, only investments maturing within three months from the date of acquisition qualify.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 02
-Paragraph 1
-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 95
-Paragraph 7
-Footnote 1
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 95
-Paragraph 8, 9, 10
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 6
-Section H
-Subsection 3

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Cash
-URI http://asc.fasb.org/extlink&oid=6506951

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Cash Equivalents
-URI http://asc.fasb.org/extlink&oid=6507016

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4273-108586

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.1)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB TOPIC 6.H.3)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13728-122682

+ Details

Inventories	9 Months Ended
Inventories	Sep. 30, 2012
Inventories [Abstract]
Inventories [Text Block]	Inventories The Company, through its PCT subsidiary, regularly enters into contracts with clients for services that have multiple stages and are dependent on one another to complete the contract and recognize revenue. The Company's inventory represents work in process for costs incurred on such projects at PCT that have not been completed. The Company reviews these projects periodically to determine that the value of each project is stated at the lower of cost or market. Inventories were $0.4 million and $0.6 million as of September 30, 2012 and December 31, 2011, respectively. The Company has also deferred revenue of approximately $0.6 million and $1.0 million of billings received as of September 30, 2012 and December 31, 2011, respectively, related to these contracts.

Loss Per Share

9 Months Ended

Sep. 30, 2012

Loss Per Share [Abstract]

Loss Per Share [Text Block]

Loss Per Share

Basic loss per share is based on the weighted effect of all common shares issued and outstanding, and is calculated by dividing net loss attributable to common shareholders by the weighted average shares outstanding during the period. Diluted loss per share, which is calculated by dividing net loss attributable to common shareholders by the weighted average number of common shares used in the basic loss per share calculation plus the number of common shares that would be issued assuming conversion of all potentially dilutive securities outstanding, is not presented as such potentially dilutive securities are anti-dilutive in all periods presented. For the nine months ended September 30, 2012 and 2011, the Company incurred net losses and therefore no common stock equivalents were utilized in the calculation of loss per share. At September 30, 2012 and 2011, the Company excluded the following potentially dilutive securities:



	September 30,
	2012	2011
Stock Options	22,389,642	17,749,895
Warrants	56,314,182	35,208,817
Series E Preferred Stock, Common stock equivalents	2,634,799	4,693,730
Restricted Shares	232,000	830,834

Fair Value Measurements

9 Months Ended

Sep. 30, 2012

Fair Value Measurements [Abstract]

Fair Value Measurements [Text Block]

Fair Value Measurements

Fair value of financial assets and liabilities that are being measured and reported are defined as the exchange price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants in the principal market at the measurement date (exit price). The Company is required to classify fair value measurements in one of the following categories:

Level 1 inputs are defined as quoted prices (unadjusted) in active markets for identical assets or liabilities that the reporting entity has the ability to access at the measurement date.

Level 2 inputs are defined as inputs other than quoted prices included within Level 1 that are observable for the assets or liabilities, either directly or indirectly.

Level 3 inputs are defined as unobservable inputs for the assets or liabilities. Financial assets and liabilities are classified based on the lowest level of input that is significant to the fair value measurement. The Company’s assessment of the significance of a particular input to the fair value measurement requires judgment, and may affect the valuation of the fair value of assets and liabilities and their placement within the fair value hierarchy levels.

The Company determined the fair value of funds invested in money market investments, which are considered trading securities, to be level 1 inputs measured by quoted prices of the securities in active markets. The money market investments are included within prepaids and other current assets on the balance sheet. The Company determined the fair value of funds invested in money market funds to be level 1. The Company determined the fair value of the embedded derivative liabilities and warrant derivative liabilities to be level 3 inputs. These inputs require material subjectivity because value is derived through the use of a lattice model that values the derivatives based on probability weighted discounted cash flows. The following table sets forth by level within the fair value hierarchy the Company’s financial assets and liabilities that were accounted for at fair value on a recurring basis as of September 30, 2012, and December 31, 2011 (in thousands):



	September 30, 2012
	Fair Value Measurements Using Fair Value Hierarchy
	Level 1		Level 2		Level 3
Money market investments	$	2,500.1	$	—	$	—
Embedded derivative liabilities	—		—		257.0
Warrant derivative liabilities	—		—		170.6
Contingent consideration	—		—		3,130.0



	December 31, 2011
	Fair Value Measurements Using Fair Value Hierarchy
	Level 1		Level 2		Level 3
Money market investments	$	2,497.4	$	—	$	—
Embedded derivative liabilities	—		—		391.7
Warrant derivative liabilities	—		—		82.7
Contingent consideration	—		—		3,130.0

Contingent consideration was recognized on October 17, 2011 in connection with the Amorcyte Merger (see Note 3). The fair value measurement of the contingent consideration obligations is determined using Level 3 inputs. The fair value of contingent consideration obligations is based on a discounted cash flow model using a probability-weighted income approach. The measurement is based upon unobservable inputs supported by little or no market activity based on our own assumptions and experience. The value of our contingent consideration is valued using a discount rate of 30%. We base the timing to complete the development and approval of this product on the current development stage of the product and the inherent difficulties and uncertainties in developing a product candidate, such as obtaining U.S. Food and Drug Administration (FDA) and other regulatory approvals. In determining the probability of regulatory approval and commercial success, we utilize data regarding similar milestone events from several sources, including industry studies and our own experience. These fair value measurements represent Level 3 measurements as they are based on significant inputs not observable in the market. Significant judgment is employed in determining the appropriateness of these assumptions as of the acquisition date and for each subsequent period. Accordingly, changes in assumptions could have a material impact on the amount of contingent consideration expense we record in any given period. Changes in the fair value of the contingent consideration obligations are recorded in our consolidated statement of operations. There were no changes in contingent consideration fair value as of September 30, 2012.

For those financial instruments with significant Level 3 inputs, the following table summarizes the activity for the three and nine months ended September 30, 2012 by type of instrument (in thousands):



	Three Months Ended					Nine Months Ended
	September 30, 2012					September 30, 2012
	Embedded Derivatives			Warrants		Embedded Derivatives			Warrants
Beginning liability balance	$	263.2		$	99.8	$	391.7		$	82.7
Change in fair value recorded in earnings	(6.2		)	70.8		(134.7		)	87.9
Ending liability balance	$	257.0		$	170.6	$	257.0		$	170.6

Some of the Company’s financial instruments are not measured at fair value on a recurring basis, but are recorded at amounts that approximate fair value due to their liquid or short-term nature, such as cash and cash equivalents, restricted cash, accounts receivable, accounts payable, notes payable and bank loans.

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 133
-Paragraph 44A, 44B
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 107
-Paragraph 15C, 15D
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 107
-Paragraph 15A
-Subparagraph a-d
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 107
-Paragraph 15B
-Subparagraph a, b
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 107
-Paragraph 3, 10, 14, 15
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 157
-Paragraph 32, 33, 34
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 159
-Paragraph 17-22, 27, 28
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 820
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6925170&loc=d3e19207-110258

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 21
-URI http://asc.fasb.org/extlink&oid=6947722&loc=d3e13537-108611

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=6957238&loc=d3e14064-108612

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=6947722&loc=d3e13433-108611

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 30
-URI http://asc.fasb.org/extlink&oid=6957238&loc=d3e14172-108612

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 16
-URI http://asc.fasb.org/extlink&oid=6947722&loc=d3e13504-108611

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 820
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=6925170&loc=d3e19296-110258

+ Details

Goodwill and Other Intangible Assets

9 Months Ended

Sep. 30, 2012

Goodwill and Other Intangible Assets [Abstract]

Goodwill and Intangible Assets [Text Block]

Goodwill and Other Intangible Assets

As of September 30, 2012 and December 31, 2011, the Company's goodwill was as follows (in thousands):



	Total

Balance at December 31, 2011	$	11,117.8

Balance at September 30, 2012	$	11,117.8

As of September 30, 2012 and December 31, 2011, the Company’s intangible assets and related accumulated amortization consisted of the following (in thousands):



		September 30, 2012				December 31, 2011
	Useful Life	Gross	Accumulated Amortization		Net	Gross	Accumulated Amortization		Net
Customer list	10 years	$1,000.0	$(170.1)		$829.9	$1,000.0	$(95.1)		$904.9
Manufacturing technology	10 years	3,900.0	(663.4	)	3,236.6	3,900.0	(370.9	)	3,529.1
Tradename	10 years	800.0	(136.1	)	663.9	800.0	(76.2	)	723.8
In process R&D	Indefinite	9,400.0	—		9,400.0	9,400.0	—		9,400.0
VSEL patent rights	19 years	669.0	(167.3	)	501.7	669.0	(140.8	)	528.2
Total Intangible Assets		$15,769.0	$(1,136.9)		$14,632.1	$15,769.0	$(683.0)		$15,086.0

Total intangible amortization expense was classified in the operating expense categories for the periods included below as follows (in thousands):



	Three Months Ended September 30,				Nine Months Ended September 30,
	2012		2011		2012		2011
Cost of revenue	$	97.5	$	135.0	$	292.5	$	376.5
Research and development	8.8		8.8		26.4		26.4
Selling, general and administrative	45.0		67.5		135.0		188.3
Total	$	151.3	$	211.3	$	453.9	$	591.2

- Definition

The entire disclosure for the aggregate amount of goodwill and a description of intangible assets, which may include (a) for amortizable intangible assets (also referred to as finite-lived intangible assets), the carrying amount, the amount of any significant residual value, and the weighted-average amortization period, (b) for intangible assets not subject to amortization (also referred to as indefinite-lived intangible assets), the carrying amount, and (c) the amount of research and development assets acquired and written off in the period, including the line item in the income statement in which the amounts written off are aggregated, if not readily apparent from the income statement. Also discloses (a) for amortizable intangibles assets in total and by major class, the gross carrying amount and accumulated amortization, the total amortization expense for the period, and the estimated aggregate amortization expense for each of the five succeeding fiscal years, (b) for intangible assets not subject to amortization the carrying amount in total and by major class, and (c) for goodwill, in total and for each reportable segment, the changes in the carrying amount of goodwill during the period (including the aggregate amount of goodwill acquired, the aggregate amount of impairment losses recognized, and the amount of goodwill included in the gain (loss) on disposal of a reporting unit). If any part of goodwill has not been allocated to a reportable segment, discloses the unallocated amount and the reasons for not allocating. For each impairment loss recognized related to an intangible asset (excluding goodwill), discloses: (a) a description of the impaired intangible asset and the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method for determining fair value, (c) the caption in the income statement or the statement of activities in which the impairment loss is aggregated, and (d) the segment in which the impaired intangible asset is reported. For each goodwill impairment loss recognized, discloses: (a) a description of the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method of determining the fair value of the associated reporting unit, and (c) if a recognized impairment loss is an estimate not finalized and the reasons why the estimate is not final. May also disclose the nature and amount of any significant adjustments made to a previous estimate of an impairment loss.

+ References + Details

Debt	9 Months Ended
Debt	Sep. 30, 2012
Debt [Abstract]
Debt [Text Block]	Debt Notes Payable As of September 30, 2012 and December 31, 2011, the Company had notes payable of approximately $183,500 and $148,100, respectively. The notes relate to certain insurance policies and equipment financings, require monthly payments, and mature within one to five years. Mortgages Payable On October 31, 2007, PCT issued a note to borrow $3,120,000 (the “Note”) in connection with its $3,818,500 purchase of condominium units in an existing building in Allendale, New Jersey (the “Property”) that PCT uses as a laboratory and stem cell processing facility. The Note is payable in 239 consecutive monthly payments of principal and interest, based on a 20 year amortization schedule; and one final payment of all outstanding principal plus accrued interest then due. The current monthly installment is $20,766, which includes interest at an initial rate of 5.00%; the interest rate and monthly installments payments are subject to adjustment on October 1, 2017. On that date, upon prior written notice, the lender has the option to declare the entire outstanding principal balance, together with all outstanding interest, due and payable in full. The Note is secured by substantially all of the assets of PCT, including a first mortgage on the Property and assignment of an amount approximately equal to eighteen months debt service held in escrow. The Note matures on October 1, 2027 if not called by the lender on October 1, 2017. The note is subject to certain debt service coverage and total debt to tangible net worth financial covenant ratios measured semi-annually. PCT was not in compliance with such covenants at the measurement date of December 31, 2011 and June 30, 2012, and obtained a covenant waiver letter from the lender for all periods through December 31, 2011 and June 30, 2012. The outstanding balance was approximately $2,622,900 at September 30, 2012 of which $118,400 is payable within twelve months. On December 6, 2010 PCT Allendale, a wholly-owned subsidiary of PCT, entered into a note for a second mortgage in the amount of $1 million on the Allendale Property with TD Bank, N.A. This loan is guaranteed by PCT, DomaniCell (a wholly-owned subsidiary of PCT, now known as NeoStem Family Storage, LLC), Northern New Jersey Cancer Associates (“NNJCA”) and certain partners of NNJCA and is subject to an annual financial covenant starting December 31, 2011. PCT was not in compliance with such covenants at the measurement date of December 31, 2011, and obtained a covenant waiver letter from the lender for all periods through December 31, 2011. The loan is for 124 months at a fixed rate of 6% for the first 64 months. The loan is callable for a certain period prior to the interest reset date. The initial four months was interest only. The outstanding balance as of September 30, 2012 is $870,800 of which $87,100 is payable within twelve months. Both mortgages are classified as current liabilities as of September 30, 2012.

- Definition

The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.

+ References + Details

Preferred Stock	9 Months Ended
Preferred Stock	Sep. 30, 2012
Preferred Stock [Abstract]
Preferred Stock [Text Block]	Preferred Stock Convertible Redeemable Series E 7% Preferred Stock On November 19, 2010, the Company sold 10,582,011 Preferred Offering Units consisting of (i) one share (“Preferred Share”) of Series E 7% Senior Convertible Preferred Stock, par value $0.01 per share, of the Company, (ii) a warrant to purchase 0.25 of a share of Common Stock (consisting of at issuance an aggregate of 1,322,486 warrants, adjusted to an aggregate of 1,747,188 as of September 30, 2012); and (iii) 0.0155 of a share of Common Stock (an aggregate of 164,418 common shares). Each Preferred Offering Unit was priced at $0.945 and total gross and net proceeds received by the Company were $10,000,000 and $8,876,700, respectively. Dividends on the Preferred Shares accrue at a rate of 7% per annum and are payable monthly in arrears. The Company is required to redeem 1/27 of the Preferred Shares monthly. Monthly dividend and principal payments began on March 21, 2011 and continue on the 19th of each month thereafter with the final payment due on May 20, 2013. Payments can be made in cash or, upon notification to the holders, in shares of Company common stock, provided certain conditions are satisfied or holders of Preferred Shares agree to waive the conditions for that payment period. As of September 30, 2012, the Company had issued 7,950,107 shares of Company common stock in payment of monthly dividends and principal, including required advance payments. The Company may pre-pay the outstanding balance of the Preferred Shares in full or in part (in increments of no less than $1,000,000) at 110% of the then outstanding balance with notice of not less than thirty days and adequate opportunity to convert. If the Company chooses to pre-pay, the outstanding balance must be paid in cash and the premium may be paid in cash or shares of Company common stock. An aggregate of $2,500,000 of the proceeds from the Preferred Offering was placed in escrow for a maximum of 2.5 years as security for the Company’s obligations relative to the Preferred Shares, and is included in other assets. Upon issuance, the Preferred Shares were convertible at an initial conversion price of $2.0004. The conversion price is subject to certain weighted average adjustments upon the occurrence of specific events, including stock dividends, stock splits, combinations and reclassifications of the Company’s common stock and if (with certain exceptions) the Company issues or sells any additional shares of common stock or common stock equivalents at a price per share less than the conversion price then in effect, or without consideration. As of September 30, 2012, the conversion price had been adjusted to $1.18. The characteristics of the Series E Preferred Stock require that this instrument be treated as mezzanine equity. The Company bifurcated the fair value of the embedded conversion options and redemption options from the preferred stock since the conversion options and certain redemption options were determined to not be clearly and closely related to the Series E Preferred Stock and recorded the fair value of the embedded conversion and redemption options as long-term derivative liabilities. The Company also recorded the fair value of the warrants as a long-term derivative liability. The fair value of the preferred stock (net of issuance costs and discounts), the embedded derivatives, and warrant derivative were approximately $2,721,100, $257,000 and $170,600, respectively, as of September 30, 2012. The Company will report changes in the fair value of the embedded derivatives and warrant derivative in earnings within other income (expense), net. For the three months ended September 30, 2012, the Company recorded a decrease in the fair value of the embedded derivatives of approximately $6,200 and an increase in the warrant derivative of approximately $70,800. For the nine months ended September 30, 2012, the Company recorded a decrease in the fair value of the embedded derivatives of approximately $134,800 and an increase in the warrant derivative of approximately $87,900. In October 2012, the Company pre-paid the outstanding balance of the Preferred Shares, and the shares are no longer outstanding (see note 16). The $2,500,000 escrowed cash was released and applied to the aggregate redemption price.

Shareholders' Equity

9 Months Ended

Sep. 30, 2012

Shareholders’ Equity [Abstract]

Shareholders' Equity [Text Block]

Shareholders' Equity

Share-based Compensation

We utilize share-based compensation in the form of stock options, warrants and restricted stock. The following table summarizes the components of share-based compensation expense for the three and nine months ended September 30, 2012 and 2011 (in thousands):



	Three Months Ended					Nine Months Ended
	September 30,					September 30,
	2012		2011			2012		2011
Cost of goods sold	$	19.8	$	26.0		$	120.1	$	71.2
Research and development	102.2		(116.8		)	362.4		500.8
Selling, general and administrative	1,794.2		1,598.6			4,988.7		7,592.8
Total share-based compensation expense	$	1,916.2	$	1,507.8		$	5,471.2	$	8,164.8

During the nine months ended September 30, 2012, the Company issued 2,649,236 shares of restricted stock. The following table summarizes the activity for stock options and warrants for the nine months ended September 30, 2012:



	Stock Options		Warrants
Outstanding at December 31, 2011	17,143,505		37,389,825

Changes during the Year:
Granted	7,167,029		30,400,525
Exercised	—		(10,160,521	)
Forfeited	(1,737,759	)	(3	)
Expired	(183,133	)	(1,315,644	)
Outstanding at September 30, 2012	22,389,642		56,314,182

Total compensation cost related to nonvested awards not yet recognized and the weighted-average periods over which the awards are expected to be recognized at September 30, 2012 were as follows (dollars in thousands):



	Stock Options		Warrants		Restricted Stock
Unrecognized compensation cost	$	2,179.9	$	94.9	$	130.6
Expected weighted-average period in years of compensation cost to be recognized	1.84		0.39		0.14

Common Stock

In March 2012, the Company completed an underwritten offering of 15,000,000 units at a purchase price of $0.40 per unit, with each unit consisting of one share of Common Stock and a five year warrant to purchase one share of Common Stock at an exercise price of $0.51 per share (the “ March 2012 Offering”). The Company sold securities in the March 2012 Offering under the Company’s previously filed shelf registration statement on Form S-3 (333-173855), which was declared effective by the Securities and Exchange Commission on June 13, 2011. The Company received gross proceeds of $6,000,000, prior to deducting underwriting discounts and offering expenses payable by the Company, for net proceeds of approximately $5,297,000. In April 2012, the underwriters in the March 2012 Offering exercised their over-allotment option for an additional 2,000,000 units. The Company received additional gross proceeds of $800,000, prior to deducting underwriting discounts, for net proceeds of approximately $744,000. Additionally in April 2012, the warrants issued in connection with the offering initially exercisable beginning on September 30, 2012, were accelerated and became exercisable immediately.

In the first nine months of 2012, we also issued securities in a number of private placements of common stock or units consisting of common stock and warrants. In the aggregate, we raised gross proceeds of approximately $6.1 million in private placements of an aggregate of approximately 11.8 million shares of Common Stock and 8.3 million five year warrants at exercise prices ranging from $.51 to $.74. The warrants have been classified as equity and will not be subject to remeasurement.

In August 2012, the Company and Aspire Capital Fund, LLC ("Aspire") entered into an amendment to the Common Stock Purchase Agreement dated September 28, 2011, providing for an extension of the 24-month term of the Purchase Agreement until September 30, 2015. Pursuant to the amendment, we agreed to issue to Aspire a five-year warrant to purchase up to 1,612,903 shares of our common stock at an exercise price of $0.60 per share (the closing price of our common stock on the date the amendment was executed).

In the first nine months of 2012, we issued 1,039,339 shares of common stock to the Company's officers and directors pursuant and subject to the terms of the Company's 2009 Equity Compensation Plan, of which 398,115 shares were issued to our officers who elected to receive common stock as compensation in lieu of cash compensation.

Warrant Exercises

In July 2012, warrant holders from the March 2012 Offering exercised an aggregate of 3,150,344 warrants at an exercise price of $.51 per share for gross proceeds of approximately $1.6 million.

To raise capital on terms that we deemed favorable, during the three months ended September 30, 2012, the Board authorized certain inducements to warrant holders to exercise outstanding common stock purchase warrants significantly before their expiration dates. The Company determined in each instance that such inducements were modifications of equity instruments, and an incremental fair value of the inducement was determined using the Black-Scholes option pricing model.

In connection with the July 2012 exercise of 2,808,140 of the warrants issued in our May-July 2012 private placement warrants at an exercise price of $0.51 per share for gross proceeds of $1.4 million, we issued to each exercising holder a new five year warrant to purchase the identical number of shares of our Common Stock as had been exercised subject to substantially the same terms as the exercised warrant, except that the per share exercise price of each new warrant is between $.66 and $.69, the closing price of our Common Stock on the date the old warrant was exercised. The incremental fair value of the inducement recorded in the three months ended September 30, 2012 was $0.4 million.

In August 2012, a warrant holder exercised warrants to purchase 2,100,000 shares of the Company' common stock at an exercise price of $0.51 per share, for gross proceeds to the Company of approximately $1.1 million. The warrants were originally issued in 2009 with an exercise price of $2.50 per share. The incremental fair value of the inducement recorded in the three months ended September 30, 2012 was $0.2 million.

In August 2012, a warrant holder exercised warrants to purchase 344,825 shares of common stock at $1.85, and 300,000 shares of common stock at $1.45 per share, respectively, for gross proceeds to the Company of approximately $1.1 million. Since the exercise prices of the warrants were significantly above the Company's stock price, the Company issued the warrant holder 1,458,952 shares of the Company's common stock as an inducement to exercise. The incremental fair value of the inducement recorded in the three months ended September 30, 2012 was $0.4 million.

In September warrant holders exercised an aggregate of 1,457,212 warrants at an exercise price of $.51 per share for gross proceeds of approximately $0.7 million. As an inducement to exercise, we paid certain warrant holders $.03 per share upon each exercise. The incremental fair value of the inducement recorded in the three months ended September 30, 2012 was $0.

- Definition

The entire disclosure for shareholders' equity, comprised of portions attributable to the parent entity and noncontrolling interest, if any, including other comprehensive income (as applicable). Including, but not limited to: (1) balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings; (2) accumulated balance for each classification of other comprehensive income and total amount of comprehensive income; (3) amount and nature of changes in separate accounts, including the number of shares authorized and outstanding, number of shares issued upon exercise and conversion, and for other comprehensive income, the adjustments for reclassifications to net income; (4) rights and privileges of each class of stock authorized; (5) basis of treasury stock, if other than cost, and amounts paid and accounting treatment for treasury stock purchased significantly in excess of market; (6) dividends paid or payable per share and in the aggregate for each class of stock for each period presented; (7) dividend restrictions and accumulated preferred dividends in arrears (in aggregate and per share amount); (8) retained earnings appropriations or restrictions, such as dividend restrictions; (9) impact of change in accounting principle, initial adoption of new accounting principle and correction of an error in previously issued financial statements; (10) shares held in trust for Employee Stock Ownership Plan (ESOP); (11) deferred compensation related to issuance of capital stock; (12) note received for issuance of stock; (13) unamortized discount on shares; (14) description, terms, and number of warrants or rights outstanding; (15) shares under subscription and subscription receivables, effective date of new retained earnings after quasi-reorganization and deficit eliminated by quasi-reorganization and, for a period of at least ten years after the effective date, the point in time from which the new retained dates; and (16) retroactive effective of subsequent change in capital structure.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Principles Board Opinion (APB)
-Number 12
-Paragraph 10
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 04
-Article 3

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Article 4
-Section 08
-Paragraph d

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Research Bulletin (ARB)
-Number 43
-Chapter 1
-Section B
-Paragraph 7, 11A
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 129
-Paragraph 2, 3, 4, 5, 6, 7, 8
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 08
-Article 4

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 5
-Paragraph 15
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 02
-Paragraph 29, 30, 31
-Article 5

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 4
-Section E

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 4
-Section C

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=6959260&loc=d3e187085-122770

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21484-112644

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21564-112644

Reference 16: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21488-112644

Reference 17: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(d),(e))
-URI http://asc.fasb.org/extlink&oid=6881521&loc=d3e23780-122690

Reference 18: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644

Reference 19: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 30
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656

Reference 20: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB TOPIC 4.E)
-URI http://asc.fasb.org/extlink&oid=6228006&loc=d3e74512-122707

Reference 21: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Preferred Stock
-URI http://asc.fasb.org/extlink&oid=6521494

Reference 22: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.29-31)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 23: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 4
-Subparagraph (SAB TOPIC 4.C)
-URI http://asc.fasb.org/extlink&oid=6959260&loc=d3e187143-122770

+ Details

Income Taxes	9 Months Ended
Income Taxes	Sep. 30, 2012
Income Taxes [Abstract]
Income Taxes [Text Block]	Income Taxes The Tax Reform Act of 1986 enacted a complex set of rules limiting the utilization of net operating loss carryforwards (“NOL”) to offset future taxable income following a corporate ownership change. The Company’s ability to utilize its NOL carryforwards is limited following a change in ownership in excess of fifty percentage points during any three-year period. Since the year 2000, the Company has had several changes in ownership which has resulted in a limitation on the Company’s ability to apply net operating losses to future taxable income. As of December 31, 2011 the Company has lost $25,994,800 or $8,838,200 in tax benefits, of net operating losses applicable to Federal income taxes which expired due to these limitations and expiration of net operating loss carryforwards. At December 31, 2011, the Company had net operating loss carryforwards of approximately $47,427,300 applicable to future Federal income taxes. The tax loss carryforwards are subject to annual limitations and expire at various dates through 2030. The Company has recorded a full valuation allowance against its net deferred tax asset because it is more likely than not that such deferred tax assets will not be realized.

- Definition

The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 08
-Paragraph h
-Article 4

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 109
-Paragraph 136, 172
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 109
-Paragraph 43, 44, 45, 46, 47, 48, 49
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 15
-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32718-109319

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32639-109319

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(h))
-URI http://asc.fasb.org/extlink&oid=6881521&loc=d3e23780-122690

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32537-109319

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32559-109319

+ Details

Discontinued Operations

9 Months Ended

Sep. 30, 2012

Discontinued Operations [Abstract]

Discontinued Operations [Text Block]

Discontinued Operations

Regenerative Medicine - China segment

In 2009, the Company began its Regenerative Medicine-China business in the People’s Republic of China (“China” or “PRC”) through its subsidiary, a wholly foreign owned entity (“WFOE”) and entered into contractual arrangements with certain variable interest entities (“VIEs”). Foreign companies have commonly used VIE structures to operate in the PRC, and while such structures are not uncommon, recently they have drawn greater scrutiny from the local Chinese business community in the PRC who have urged the PRC State Council to clamp down on these structures. In addition, in December 2011, China’s Ministry of Health announced its intention to more tightly regulate stem cell clinical trials and stem cell therapeutic treatments in the PRC, which has created uncertainty regarding the ultimate regulatory environment in the PRC. Accordingly, the Company took steps to restrict, and ultimately eliminate, its regenerative medicine business in the PRC. As a result of these steps, the Company has discontinued its operations in its Regenerative Medicine-China business. The Company has determined that any liability arising from the activities of the WFOE and the VIEs will likely be limited to the net assets currently held by each entity. As of March 31, 2012, the Company recognized the following loss on exit of the Regenerative Medicine-China business (in thousands):



Cash	$	195.1
Prepaid expenses and other current assets	14.9
Property, plant and equipment, net	1,023.7
Other Assets	330.5
Accounts payable	(177.1		)
Accrued liabilities	(79.2		)
Accumulated comprehensive income	(169.9		)
Loss on exit of segment	$	1,138.0

The operations and cash flows of the Regenerative Medicine - China business were eliminated from ongoing operations as a result of our exit decision, and the Company will not have continuing involvement in this business going forward. The operating results of the Regenerative Medicine – China business for the three and nine months ended September 30, 2012 and 2011, which are included in discontinued operations, were as follows (in thousands):



	Three Months Ended September 30,					Nine Months Ended September 30,
	2012		2011			2012			2011
Revenue	$	—	$	98.8		$	52.3		$	148.9
Cost of revenues	—		(31.3		)	(30.6		)	(49.4		)
Research and development	—		93.6			(103.3		)	(64.5		)
Selling, general, and administrative	—		(782.3		)	(497.3		)	(1,572.3		)
Other income (expense)	—		1.4			(6.8		)	(11.3		)
Loss on exit of segment	—		—			(1,138.0		)	—
Loss from discontinued operations	$	—	$	(619.8	)	$	(1,723.7	)	$	(1,548.6	)

The summary of the assets and liabilities related to Regenerative Medicine-China discontinued operations as of December 31, 2011 was as follows (in thousands):



	December 31, 2011
Assets:
Cash and cash equivalents	$	103.3
Prepaid expenses and other current assets	284.4
Property, plant and equipment, net	1,256.8
Other Assets	149.0
	$	1,793.5
Liabilities:
Accounts payable	$	177.8
Accrued liabilities	31.0
	$	208.8

On October 12, 2012, the Company signed a settlement agreement with Yeyan Zhang, legal representative of the WFOE, to arrange for the orderly disposition and liquidation of the WFOE and the VIEs, and to formally assign the Company’s rights, title and interest of the WFOE to Mr. Zhang.

Pharmaceutical Manufacturing - China segment

On June 18, 2012, the Company announced that it had entered into a definitive agreement to sell its 51% interest in Erye (the "Equity Purchase Agreement") for approximately $12.3 million in cash and the return to the Company of (i) 1,040,000 shares of the Company's Common Stock and (ii) the cancellation of 1,170,000 options and 640,000 Common Stock warrants. The closing of the transaction is subject to satisfaction of certain conditions. The Erye divestiture closed on November 13, 2012 (see Note 16).

In July 2012, the Company received from the Purchasers the initial $1,228,000 down payment (10% of the total cash purchase price for the Erye Sale). In August 2012, the Purchasers paid $4,912,000 (being 40% of the total cash purchase price for the Erye Sale) into escrow (the "Second Purchase Price Payment"), as follows: (x) $2,456,000 (the "Offshore Second Purchase Price Payment") was deposited by the Purchasers into a U.S.-based escrow account (the "Offshore Escrow Account") (the Equity Purchase Agreement providing that the Offshore Second Purchase Price Payment shall be released to our subsidiary CBH upon the receipt of approval of the Erye Sale by the PRC Ministry of Commerce and/or its local counterparts as applicable ("MOFCOM Transfer Approval")) and (y) the RMB equivalent of $2,456,000 (the "Onshore Second Purchase Price Payment") was deposited by the Purchasers into an escrow account inside the PRC (the "Onshore Escrow Account"). In September 2012, the Purchasers deposited the RMB equivalent of $6,140,000 (the remaining 50% of the total cash purchase price for the Erye Sale), into an escrow account inside the PRC (the "Onshore Escrow Account"). Also during September 2012, $1,500,000 was released from the Offshore Escrow Account to the Company. As a result, as of September 30, 2012, the Company has received $2,728,000 of the sale proceeds, which are non-refundable and have no restrictions. These sale proceeds are included in Cash and Cash Equivalents and Other Liabilities on the balance sheet.

The operations and cash flows of the Pharmaceutical Manufacturing - China business will be eliminated from ongoing operations with the sale of the Company's 51% interest in Erye. The operating results of the Pharmaceutical Manufacturing - China business for the three and nine months ended September 30, 2012 and 2011, including the estimated asset impairments based on the definitive agreement purchase price, were as follows (in thousands):



	Three Months Ended September 30,						Nine Months Ended September 30,
	2012			2011			2012			2011
Revenue	$	20,036.4		$	15,513.0		$	57,254.7		$	49,806.0
Cost of revenues	(11,551.5		)	(11,905.1		)	(37,131.5		)	(36,207.1		)
Research and development	(611.8		)	(782.5		)	(2,231.5		)	(1,885.3		)
Selling, general, and administrative	(3,514.7		)	(2,107.4		)	(9,714.8		)	(8,233.5		)
Other expense	(0.9		)	(583.2		)	(1,008.3		)	(949.3		)
Provision for income taxes	(1,029.9		)	(26.2		)	(1,535.4		)	(907.6		)
Asset impairments	(3,175.5		)	—			(31,170.1		)	—
(Loss) income from discontinued operations	$	152.1		$	108.6		$	(25,536.9	)	$	1,623.2

The summary of the assets and liabilities related to Pharmaceutical Manufacturing - China discontinued operations as of September 30, 2012 and December 31, 2011, respectively, were as follows (in thousands):



	September 30, 2012		December 31, 2011
Cash and cash equivalents	$	10,789.5	$	8,707.0
Restricted cash	2,892.4		—
Accounts receivable, net	7,105.3		5,525.7
Inventory	15,141.9		16,505.7
Deferred income taxes	344.2		463.7
Prepaid expenses and other current assets	750.9		777.5
Property, plant and equipment, net	37,327.3		36,490.4
Land use rights, net	3,021.5		4,872.4
Goodwill	—		8,495.7
Intangible assets, net	—		21,846.4
Other assets	2,821.1		2,459.9
Total assets	$	80,194.1	$	106,144.4

Accounts payable	$	8,730.5	$	7,950.3
Accrued liabilities	2,874.7		1,705.8
Bank loans	17,369.0		15,712.0
Notes payable	6,541.3		—
Income tax payable	2,142.3		621.6
Deferred income taxes	5,902.4		6,177.4
Unearned revenue	1,544.1		1,315.4
Amount due related parties	8,519.2		20,862.7
Total Liabilities	$	53,623.5	$	54,345.2

Statutory Reserves

Pursuant to laws applicable to entities incorporated in the PRC, the PRC subsidiaries are prohibited from distributing their statutory capital and are required to appropriate from PRC GAAP profit after tax to other non-distributable reserve funds. These reserve funds include one or more of the following: (i) a general reserve, (ii) an enterprise expansion fund and (iii) a staff bonus and welfare fund. Subject to certain cumulative limits (i.e., 50% of the registered capital of the relevant company), the general reserve fund requires annual appropriation at 10% of after tax profit (as determined under accounting principles generally accepted in the PRC at each year-end); the appropriation to the other funds are at the discretion of the subsidiaries.

The general reserve is used to offset extraordinary losses. Subject to approval by the relevant authorities, a company may, upon a resolution passed by the shareholders, convert the general reserve into registered capital provided that the remaining general reserve after the conversion shall be at least 25% of the registered capital of the subsidiary before the capital increase as a result of the conversion. The staff welfare and bonus reserve is used for the collective welfare of the employees of the company. The enterprise expansion reserve is for the expansion of the subsidiary’s operations and can also be converted to registered capital upon a resolution passed by the shareholders subject to approval by the relevant authorities. These reserves represent appropriations of the retained earnings determined in accordance with Chinese law, and are not distributable as cash dividends to the parent company, NeoStem. Statutory reserves are $2,479,500 and $2,488,000 as of September 30, 2012 and December 31, 2011, respectively.

Relevant PRC statutory laws and regulations permit payment of dividends by the Company’s PRC subsidiaries only out of their accumulated earnings, if any, as determined in accordance with PRC accounting standards and regulations. As a result of these PRC laws and regulations, the Company’s PRC subsidiaries are restricted in their ability to transfer a portion of their net assets either in the form of dividends, loans or advances. The restricted amount was $186,800 at September 30, 2012 and $185,000 at December 31, 2011.

Related Party Transactions

At September 30, 2012 and December 31, 2011, Erye owed EET, the 49% shareholder of Erye, approximately $8.5 million and $20.9 million, respectively, which represents dividends paid and loaned back to Erye. September 30, 2012 and December 31, 2011 the interest rate on this loan was 6.00% and 6.56%, respectively. In the three months ended September 30, 2012, Erye paid EET approximately $0.7 million of accrued interest, and $11.6 million of loan principal.

Pursuant to the terms and conditions of the October 2009 Erye Joint Venture Agreement, dividend distributions to EET and the Company’s subsidiary will be made in proportion to their respective ownership interests in Erye; provided, however, that for the three-year period commencing on the first day of the first fiscal quarter after the Joint Venture Agreement became effective distributions are made as follows: for undistributed profits generated subsequent to the acquisition date: (i) the 49% of undistributed profits (after tax) of the joint venture due EET will be distributed to EET and lent back to Erye to help finance costs in connection with its construction of and relocation to a new facility (to be repaid gradually after construction is completed); and (ii) of the net profit (after tax) of the joint venture due the Company, 45% will be provided to Erye as part of the new facility construction fund and will be characterized as additional paid-in capital for the Company’s 51% interest in Erye, and 6% will be distributed to the Company. It was contemplated by the Joint Venture Agreement that the construction would continue for three years. As such, 45% of the dividend we would be entitled to by reason of our 51% ownership would remain in Erye through 2012 to complete the construction while EET would loan back their dividend during the same period at a prevailing bank interest rate. In January 2011, a dividend totaling approximately $13,671,100 based on earnings for Fiscal Year 2009 was declared and approximately $6,698,800 was distributed to EET and lent back to Erye and approximately $6,972,300 due the Company was reinvested and re-characterized as additional paid-in capital in the business. In April 2011, a dividend totaling $10,259,700 based on earnings for Fiscal Year 2010 was declared and approximately $5,027,300 was distributed to EET and lent back to Erye, and approximately $5,232,400 due the Company was reinvested and re-characterized as additional paid-in capital in the business. A10% withholding tax was required on dividends payable to the Company. As a result, Erye withheld approximately $1,220,500 in taxes related to the Company’s Fiscal Year 2009 and 2010 dividend amounts, and such amount has been paid to the local Chinese tax authorities as of December 31, 2011.

Contingencies

Chinese regulatory approvals — The Company has determined that it did not obtain all Chinese regulatory approvals (and associated registrations) required to reflect the legal title of its interest in Erye as being held by the proper entity within our group which is its current beneficial owner as that term is used under U.S. law. The Company believes that this issue will become moot through the proposed sale of the Company's equity interest in Erye to Erye's Chinese joint venture partner, EET. We have also secured Erye's agreement to obtain any necessary remedial approvals and filings in the event the Erye equity sale was not to close. As the Company has already signed a definitive agreement with EET with respect to the sale of its Erye equity interest, the Company believes that the risk of possible tax exposure and other regulatory issues in PRC associated with the foregoing filing deficiency is relatively contained.

Xiangbei Welman Pharmaceutical Co., Ltd. v. Suzhou Erye Pharmaceutical Co., Ltd. and Hunan Weichu Pharmacy Co., Ltd. involves a copyright infringement lawsuit brought in 2009 whereby Welman claimed the package inserts with respect to a particular antibiotics complex manufactured by Erye (the "Product") infringed its copyright. Erye was enjoined from copying and using the package inserts on the Product and from selling the Product with the package inserts and Welman was awarded 50,000 RMB Erye has filed application for a retrial of the previous lawsuit brought by Welman to the Hunan High Court, which application filing was accepted by the court, with the court opening date for retrial not determined yet.

In July 2011, a new copyright infringement lawsuit was brought by Welman against Erye claiming that Erye was not complying with the earlier judgment enjoining them from copying and using the package inserts for the Product. The Changsha Intermediate Court was applied to for property preservation and issued a civil decision freezing Erye's bank deposit of up to 50 million RMB, or to seal up or detain Erye's other properties of equal value. As of September 30, 2012, approximately 17.9 million RMB (approximately $2.8 million) had been frozen in six Erye bank accounts. Erye has contended that jurisdiction is not proper, and the case is now in review of the Hunan High Court.

In July 2011, another copyright infringement lawsuit was instituted by Welman against Erye in the Guangzhou Intermediate Court to (i) enjoin Erye from copying and using the package inserts from the Product and selling the drugs with the aforesaid package inserts; and (ii) award Welman economic losses of approximately 2 million RMB against Erye. The case has since been withdrawn by Welman. Welman made an application for a preliminary injunction to prohibit Erye from copying and using the package inserts from the Product and selling the drugs with the aforesaid package inserts; Welman's application was denied by the Court on September 6, 2011. Welman subsequently obtained a preliminary injunction from a lower court Guangzhou Haizhu District Court on September 14, 2011. However, on October 28, 2011, upon the appeal by Erye, the Haizhu District Court issued a decision withdrawing the preliminary injunction. Welman again applied for on April 13, 2012 and obtained on April 17, 2012 a preliminary injunction from another lower court Guangzhou Baiyun District Court. Erye has applied for court reconsideration on that granted preliminary injunction. On July 2, 2012, Guangzhou Baiyun District Court issued a decision withdrawing the injunction. On September 12, 2012, Erye brought an action against Welman at Zhuhai District Court for Welman's “wrongful application for preliminary injunction”, demanding that Welman compensate for Erye's economic loss of approximately RMB 1,000,000. The case has been accepted by Zhuhai District Court for further examination.

- Definition

The entire disclosure for the facts and circumstances leading to the completed or expected disposal, manner and timing of disposal, the gain (loss) recognized in the income statement and the income statement caption that includes that gain (loss), amounts of revenues and pretax profit or loss reported in discontinued operations, the segment in which the disposal group was reported, and the classification (whether sold or classified as held for sale) and carrying value of the assets and liabilities comprising the disposal group. Includes all disposal groups, including those classified as components of the entity (discontinued operations).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 144
-Paragraph 43-48
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6391110&loc=d3e2941-110230

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6360339&loc=d3e1361-107760

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=6360339&loc=d3e1510-107760

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 45
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=6892542&loc=d3e1020-107759

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 45
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6892542&loc=d3e1012-107759

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 45
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6892542&loc=d3e957-107759

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6360339&loc=d3e1474-107760

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 45
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=6390789&loc=d3e2443-110228

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6360339&loc=d3e1436-107760

+ Details

Related Party Transactions	9 Months Ended
Related Party Transactions	Sep. 30, 2012
Related Party Transactions [Abstract]
Related Party Transactions [Text Block]	Related Party Transactions On June 18, 2012, we and our subsidiary, China Biopharmaceuticals Holdings, Inc. (“CBH”), entered into an Equity Purchase Agreement (the “Equity Purchase Agreement”) with Fullbright Finance Limited, a limited liability company organized under the laws of the British Virgin Islands (“Fullbright”), Suzhou Erye Economy & Trading Co., Ltd., a limited liability company organized under the laws of the People's Republic of China (“EET” and together with Fullbright, each a “Purchaser” and collectively, the “Purchasers”), and Erye, which Equity Purchase Agreement provides for the sale by NeoStem and CBH to the Purchasers (the “Erye Sale”) of our 51% ownership interest in Erye (the “Erye Interest”). EET, one of the Purchasers party to the Equity Purchase Agreement, is the holder of the minority 49% ownership interest in Erye, and is a party along with our subsidiary CBH to the Joint Venture Agreement governing the ownership of the respective interests in Erye. Fullbright is an affiliate of EET. Mr. Shi Mingsheng (a member of our Board of Directors, and Chairman of the Board of Erye) and Madam Zhang Jian (the General Manager of Erye, and formerly our Vice President of Pharmaceutical Operations) are the principal equity holders of each of EET and Fullbright. Fullbright has assigned all its rights and obligations under the Equity Purchase Agreement (except for its obligations in respect of the return of certain NeoStem securities held by it as part of the purchase price, and its obligations in respect of closing deliverables) to Highacheive Holdings Limited, a limited liability company organized under the laws of the British Virgin Islands and an affiliate of Fullbright (“Highacheive”). As a result of the assignment, the Purchasers of our Erye Interest will be EET and Highacheive. See Note 13 for a description of the consideration to be paid by the Purchasers pursuant to the Equity Purchase Agreement. The Erye divestiture closed on November 13, 2012 (see Note 16).

- Definition

The entire disclosure for related party transactions, including the nature of the relationship(s), a description of the transactions, the amount of the transactions, the effects of any change in the method of establishing the terms of the transaction from the previous period, stated interest rate, expiration date, terms and manner of settlement per the agreement with the related party, and amounts due to or from related parties. If the entity and one or more other entities are under common ownership or management control and this control affects the operating results or financial position, disclosure includes the nature of the control relationship even if there are no transactions between the entities. Disclosure may also include the aggregate amount of current and deferred tax expense for each statement of earnings presented where the entity is a member of a group that files a consolidated tax return, the amount of any tax related balances due to or from affiliates as of the date of each statement of financial position presented, the principal provisions of the method by which the consolidated amount of current and deferred tax expense is allocated to the members of the group and the nature and effect of any changes in that method. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Article 4
-Section 08
-Paragraph k

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Article 3A
-Section 04
-Paragraph b

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 57
-Paragraph 1-4
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 850
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39622-107864

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 850
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 850
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(k))
-URI http://asc.fasb.org/extlink&oid=6881521&loc=d3e23780-122690

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 850
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 850
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39678-107864

+ Details

Commitments and Contingencies

9 Months Ended

Sep. 30, 2012

Commitments and Contingencies [Abstract]

Commitments and Contingencies [Text Block]

Commitments and Contingencies

Lease Commitments

The Company leases offices and certain equipment under certain noncancelable operating leases that expire from time to time through 2017. In August 2012, the Company signed a new lease for a larger space at its current executive offices at 420 Lexington Avenue, New York, NY 10170. The new lease is believed to be sufficient space for the near future. The lease term began in September 2012 and shall extend through June 2015. The base monthly rent, which includes storage space, averages approximately $27,000 per month, with subleases that will aggregate approximately $7,500 per month. This property is used as the Company's corporate headquarters.

A summary of future minimum rental payments required under operating leases that have initial or remaining terms in excess of one year as of September 30, 2012 are as follows (in thousands):



Years ended	Operating Leases
2012	$	410.8
2013	1,226.5
2014	962.1
2015	739.2
2016	563.9
Thereafter	293.2
Total minimum lease payments	$	4,195.7

Expense incurred under operating leases was approximately $377,300 and $1,225,500 for the three and nine months ended September 30, 2012, respectively, and $434,600 and $1,376,100 for the three and nine months ended September 30, 2011, respectively.

Contingencies

Under license agreements with third parties the Company is typically required to pay maintenance fees, make milestone payments and/or pay other fees and expenses and pay royalties upon commercialization of products. The Company also sponsors research at various academic institutions, which research agreements generally provide us with an option to license new technology discovered during the course of the sponsored research.

In connection with the issuance to investors and service providers of many of the shares of the Company’s common stock and warrants to purchase common stock previously disclosed and described herein, the Company granted the holders registration rights providing for the registration of such shares of common stock and shares of common stock underlying warrants on a registration statement to be filed with the Securities and Exchange Commission (“SEC”) so as to permit the resale of those shares. Certain of the registration rights agreements provided for penalties for failure to file or failure to obtain an effective registration statement. With respect to satisfying its obligations to the holders of these registration rights, the Company has been in various situations. The Company had previously filed a registration statement as required for some of the holders, and in May 2011 filed a registration statement for all of the holders (except for holders whose shares of Common Stock were currently salable under Rule 144 of the Securities Act or who waived certain rights); such registration statement was declared effective by the SEC on September 30, 2011. The Company has certain obligations to maintain the effectiveness of this registration statement. Certain holders who had outstanding registration rights had previously waived their registration rights or were subject to lock-up agreements. No holder has yet asserted any claim against the Company with respect to a failure to satisfy any registration obligations. Were someone to assert a claim against the Company for breach of registration obligations, the Company believes it has several defenses that would result in relieving it from some or any liability, although no assurances can be given. The Company also notes that damage claims may be limited, as (i) most shares of Common Stock as to which registration rights attached are either now registered or currently salable under Rule 144 of the Securities Act or are otherwise currently subject to other restrictions on sale and (ii) the shares of Common Stock underlying warrants with registration rights are now registered, and during much of the relevant periods the warrants with registration rights generally have been out of the money, were subject to lock-up agreements and/or the underlying shares of Common Stock were otherwise subject to restrictions on resale. Accordingly, were holders to assert claims against the Company based on breach of the Company’s obligation to register, the Company believes that the Company’s maximum exposure would not be material.

- Definition

The entire disclosure for commitments and contingencies.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name FASB Interpretation (FIN)
-Number 14
-Paragraph 3
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 5
-Paragraph 9, 10, 11, 12
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.25)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 450
-SubTopic 20
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6952336&loc=d3e14435-108349

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 460
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=6398077&loc=d3e12565-110249

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 440
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6394976&loc=d3e25287-109308

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6449706&loc=d3e16207-108621

+ Details

Subsequent Events	9 Months Ended
Subsequent Events	Sep. 30, 2012
Subsequent Events [Abstract]
Subsequent Events [Text Block]	Subsequent Events In October 2012 warrant holders from the March 2012 Offering exercised an aggregate of 690,311 warrants at an exercise price of $.51 per share for an aggregate consideration of approximately $352,000. As an inducement to exercise, we agreed to pay certain warrant holders $.03 per share for each warrant exercised. The Company's mergers and acquisitions and finance committees of the board of directors authorized the exercise inducement on July 23, 2012. On October 10, 2012, a warrant holder exercised its warrants to purchase 225,000 shares of common stock at $1.45, for gross proceeds to the Company of $326,250. Since the exercise prices of the warrants were above the Company's stock price, the Company agreed to pay the holder an inducement fee equal to the difference between the per share exercise price and $.72 (one penny above the closing market price on the date the agreement was signed). The Company's board of directors authorized the exercise inducement on October 8, 2012. On October 25, 2012, the Company completed the redemption of all 2,351,558 outstanding shares of its Series E 7% Senior Convertible Preferred Stock, par value $0.01 per share (the “Series E Preferred Stock”), for an aggregate cash redemption price of approximately $3.4 million, $2.5 million of which was funded by money placed into escrow when the Series E Preferred stock was issued in November 2010. Also on October 25, 2012, the Company filed a Certificate of Elimination of the Series E 7% Senior Convertible Preferred Stock of NeoStem, Inc. with the Secretary of State of the State of Delaware to eliminate its Series E Preferred Stock, all of the outstanding shares of Series E Preferred Stock having been redeemed by the Company. The Company entered into a Purchase Agreement with Aspire Capital Fund, LLC in September 2011, as amended on August 23, 2012, pursuant to which Aspire Capital committed to the purchase of up to $20 million of shares of the Company’s Common Stock over the term of that Agreement, subject to certain terms and conditions, including a floor price as set forth in the Agreement. From October 22, 2012 through November 12, 2012, Aspire has purchased 2,300,000 shares of the Company's common stock for an aggregate consideration of approximately $1.5 million. On November 8, 2012, the Company consummated a private placement and issued an aggregate of 833,333 shares of restricted common stock at a purchase price of $.60 per share for an aggregate consideration of $500,000. The Company's board of directors authorized the the terms of the private placement on October 8, 2012. On November 13, 2012 (the “Closing Date”), the Company completed the divestiture (the “Erye Sale”) of our 51% interest (the “Erye Interest”) in Suzhou Erye Pharmaceuticals Company Ltd., a Sino-foreign equity joint venture with limited liability organized under the laws of the People's Republic of China primarily engaged in the manufacture of generic antibiotics (“Erye”), to Suzhou Erye Economy & Trading Co., Ltd., a limited liability company organized under the laws of the People's Republic of China (“EET”), and Highacheive Holdings Limited, a limited liability company organized under the laws of the British Virgin Islands (“Highacheive” and together with EET, each a “Purchaser” and collectively the “Purchasers”). The Erye Sale was consummated pursuant to the terms and conditions of the Equity Purchase Agreement, dated as of June 18, 2012 (as amended, the “Equity Purchase Agreement”), by and among our Company, China Biopharmaceuticals Holdings, Inc., a Delaware corporation and a wholly-owned subsidiary of NeoStem (“CBH”), EET, Highacheive, Fullbright Finance Limited, a limited liability company organized under the laws of the British Virgin Islands (“Fullbright”), and Erye. Pursuant to the Equity Purchase Agreement, the aggregate purchase price paid to us by the Purchasers for the Erye Interest consisted of (i) $12,280,000 in cash, (ii) the return to our Company of 1,040,000 shares of NeoStem common stock and (iii) the cancellation of 1,170,000 options and 640,000 warrants. On the Closing Date, the balance of the amount held in escrow, was released to the Company, the common stock was delivered to the Company, the options and warrants were canceled, and all interest of the Company in Erye was transferred to the Purchasers. On November 13, 2012, the Company entered into an amendment of its employment agreement with Dr. Robin L. Smith, pursuant to which, as previously amended (the “Agreement”), Dr. Smith serves as Chairman of the Board and Chief Executive Officer of the Company. Pursuant to the amendment, (i) the term of the Agreement was extended for two years to December 31, 2014; (ii) Dr. Smith's annual base salary was increased to $495,000; (iii) Dr. Smith will be eligible to receive a cash bonus for each of 2013 and 2014, based on a target amount of 50% of annual base salary assuming good progress toward the accomplishment of objectives set for Dr. Smith and the Company by the Compensation Committee, and which may be awarded in an amount up to 100% of annual base salary for extraordinary performance, all as determined by the Compensation Committee; (iv) all unvested options held by Dr. Smith as of the date of the amendment were immediately vested; (v) a failure to renew the Agreement at the end of the term regardless of reason shall be treated as a termination by the Company without cause; (vi) upon the Company's termination of Dr. Smith's employment without cause or by Dr. Smith with good reason, (a) the Company is to pay Dr. Smith her base salary and COBRA premiums for one year following the termination plus the previous year's annual bonus payment, and (b) all of Dr. Smith's stock options which are vested as of the termination date plus any additional options that would have vested by the passage of time during the 12 month period following such date (which additional options shall become immediately and fully vested as of the termination date) shall remain exercisable for the balance of their 10 year term; (vii) in the event the Company terminates Dr. Smith's employment with cause or Dr. Smith resigns, the Company is to pay Dr. Smith her then current base salary and COBRA premiums for one year; and (viii) any vested options previously or hereafter granted to Dr. Smith during the remainder of the term shall remain exercisable notwithstanding any termination of employment for the full option term until the expiration date.

Summary of Significant Accounting Policies (Policies)	9 Months Ended
Summary of Significant Accounting Policies (Policies)	Sep. 30, 2012
Summary of Significant Accounting Policies [Abstract]
Receivables, Policy [Policy Text Block]	Accounts Receivable Accounts receivable are carried at original invoice amount less an estimate made for doubtful accounts. The Company applies judgment in connection with establishing the allowance for doubtful accounts. Specifically, the Company analyzes the aging of accounts receivable balances, historical bad debts, customer concentration and credit-worthiness, current economic trends and changes in the Company’s customer payment terms. Significant changes in customer concentrations or payment terms, deterioration of customer credit-worthiness or weakening economic trends could have a significant impact on the collectability of the receivables and the Company’s operating results. If the financial condition of the Company’s customers were to deteriorate, resulting in an impairment of their ability to make payments, additional allowances may be required. Management regularly reviews the aging of receivables and changes in payment trends by its customers, and records a reserve when it believes collection of amounts due are at risk.
Revenue Recognition, Policy [Policy Text Block]	Revenue Recognition Clinical Services: The Company recognizes revenue for its cell development and manufacturing services based on the terms of individual contracts. Revenues associated with cell development services which contain multiple stages that do not have stand-alone values and are dependent upon one another are recognized as revenue on a completed contract basis. Cell services and manufacturing services which have separate and distinct arrangements, and the Company is paid for time and materials or for fixed monthly amounts is recognized as revenue when efforts are expended or contractual terms have been met. Clinical Services Reimbursements: The Company separately charges the customers for the expenses associated with certain consumable resources (reimbursable expenses) that are specified in each clinical services contract. On a monthly basis, the Company bills customers for reimbursable expenses and immediately recognizes these billings as revenue, as the revenue is deemed earned as reimbursable expenses are incurred. For the three months ended September 30, 2012 and 2011, clinical services reimbursements were $0.9 million and $0.7 million, respectively. For the nine months ended September 30, 2012 and 2011, clinical services reimbursements were $2.9 million and $1.8 million, respectively. Processing and Storage Services: The Company recognizes revenue related to the collection and cryopreservation of cord blood and autologous adult stem cells when the cryopreservation process is completed which is approximately twenty-four hours after cells have been collected. Revenue related to advance payments of storage fees is recognized ratably over the period covered by the advance payments. New Accounting Pronouncements In July 2012, the FASB issued ASU 2012-02, “Intangibles - Goodwill and Other (Topic 350) - Testing Indefinite-Lived Intangible Assets for Impairment.” The guidance is intended to simplify impairment testing of indefinite-lived intangible assets such as In-Process Research and Development by first assessing qualitative factors to determine whether it is “more likely than not” that the fair value of an asset is less than its carrying amount as a basis for determining whether it is necessary to perform a quantitative impairment test. The more-likely-than-not threshold is defined as having a likelihood of more than 50%. This guidance is effective for annual and interim tests performed for fiscal years beginning after September 15, 2012. The adoption of this guidance is not expected to have a significant impact on the Company's financial position or results of operations.

- Definition

Disclosure of accounting policy for trade and other accounts receivable, and finance, loan and lease receivables, including those classified as held for investment and held for sale. This disclosure may include (1) the basis at which such receivables are carried in the entity's statements of financial position (2) how the level of the valuation allowance for receivables is determined (3) when impairments, charge-offs or recoveries are recognized for such receivables (4) the treatment of origination fees and costs, including the amortization method for net deferred fees or costs (5) the treatment of any premiums or discounts or unearned income (6) the entity's income recognition policies for such receivables, including those that are impaired, past due or placed on nonaccrual status and (7) the treatment of foreclosures or repossessions (8) the nature and amount of any guarantees to repurchase receivables.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 114
-Paragraph 20
-Subparagraph b
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Emerging Issues Task Force (EITF)
-Number 92-5
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Statement of Position (SOP)
-Number 01-6
-Paragraph 13
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 02
-Paragraph 3-5
-Article 5

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18780-107790

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-URI http://asc.fasb.org/subtopic&trid=2196772

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 20
-URI http://asc.fasb.org/subtopic&trid=2196816

+ Details

- Definition

Disclosure of accounting policy for revenue recognition. If the entity has different policies for different types of revenue transactions, the policy for each material type of transaction is generally disclosed. If a sales transaction has multiple element arrangements (for example, delivery of multiple products, services or the rights to use assets) the disclosure may indicate the accounting policy for each unit of accounting as well as how units of accounting are determined and valued. The disclosure may encompass important judgment as to appropriateness of principles related to recognition of revenue. The disclosure also may indicate the entity's treatment of any unearned or deferred revenue that arises from the transaction.

+ References + Details

The Business (Tables)

9 Months Ended

Sep. 30, 2012

The Business [Abstract]

Subsidiary [Table Text Block]

The consolidated financial statements include the accounts of NeoStem, Inc. and its wholly owned and partially owned subsidiaries and affiliates as listed below:



Entity	Percentage of Ownership	Location
NeoStem, Inc.	Parent Company	United States of America
NeoStem Therapies, Inc.	100%	United States of America
Stem Cell Technologies, Inc.	100%	United States of America
Amorcyte, LLC	100%	United States of America
CBH Acquisition LLC	100%	United States of America
China Biopharmaceuticals Holdings, Inc. (CBH)	100% owned by CBH Acquisition LLC	United States of America
Suzhou Erye Pharmaceuticals Company Ltd. (1)	51% owned by CBH	People’s Republic of China
Progenitor Cell Therapy, LLC (PCT)	100%	United States of America
NeoStem Family Storage, LLC	100% owned by PCT	United States of America
Athelos Corporation	80.1% owned by PCT	United States of America
PCT Allendale, LLC	100% owned by PCT	United States of America

Acquisitions (Tables)

9 Months Ended

Sep. 30, 2012

Acquisitions [Abstract]

Schedule of Business Acquisitions, by Acquisition [Table Text Block]

The fair value of assets acquired and liabilities assumed on October 17, 2011 is as follows (in thousands):



Cash	$	92.9
Prepaid Expenses	178.2
In Process R&D	9,400.0
Goodwill	4,104.5
Accounts Payable & Accrued Liabilities	1,177.1
Deferred Tax Liability	3,774.7
Amount Due Related Party	340.4

- Definition

Tabular disclosure of a material business combination completed during the period, including background, timing, and recognized assets and liabilities. This table does not include leveraged buyouts.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 141
-Paragraph 51
-Subparagraph a
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 141
-Paragraph 52
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 141R
-Paragraph 68
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 141R
-Appendix F
-Paragraph F4
-Subparagraph e

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6972119&loc=d3e1392-128463

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6972119&loc=d3e1486-128463

+ Details

Loss Per Share (Tables)

9 Months Ended

Sep. 30, 2012

Loss Per Share [Abstract]

ScheduleOfDilutiveSecuritiesExcludedFromComputationOfEarningsPerShare [Table Text Block]

At September 30, 2012 and 2011, the Company excluded the following potentially dilutive securities:



	September 30,
	2012	2011
Stock Options	22,389,642	17,749,895
Warrants	56,314,182	35,208,817
Series E Preferred Stock, Common stock equivalents	2,634,799	4,693,730
Restricted Shares	232,000	830,834

Fair Value Measurements (Tables)

9 Months Ended

Sep. 30, 2012

Fair Value Measurements [Abstract]

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis, Valuation Techniques [Table Text Block]

The following table sets forth by level within the fair value hierarchy the Company’s financial assets and liabilities that were accounted for at fair value on a recurring basis as of September 30, 2012, and December 31, 2011 (in thousands):



	September 30, 2012
	Fair Value Measurements Using Fair Value Hierarchy
	Level 1		Level 2		Level 3
Money market investments	$	2,500.1	$	—	$	—
Embedded derivative liabilities	—		—		257.0
Warrant derivative liabilities	—		—		170.6
Contingent consideration	—		—		3,130.0



	December 31, 2011
	Fair Value Measurements Using Fair Value Hierarchy
	Level 1		Level 2		Level 3
Money market investments	$	2,497.4	$	—	$	—
Embedded derivative liabilities	—		—		391.7
Warrant derivative liabilities	—		—		82.7
Contingent consideration	—		—		3,130.0

Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]



	Three Months Ended					Nine Months Ended
	September 30, 2012					September 30, 2012
	Embedded Derivatives			Warrants		Embedded Derivatives			Warrants
Beginning liability balance	$	263.2		$	99.8	$	391.7		$	82.7
Change in fair value recorded in earnings	(6.2		)	70.8		(134.7		)	87.9
Ending liability balance	$	257.0		$	170.6	$	257.0		$	170.6

- Definition

Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes during the period attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issuances, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.

+ References + Details

Goodwill and Other Intangible Assets (Tables)

9 Months Ended

Sep. 30, 2012

Goodwill and Other Intangible Assets [Abstract]

Schedule of Goodwill [Table Text Block]

As of September 30, 2012 and December 31, 2011, the Company's goodwill was as follows (in thousands):



	Total

Balance at December 31, 2011	$	11,117.8

Balance at September 30, 2012	$	11,117.8

Schedule of Finite-Lived Intangible Assets by Major Class [Table Text Block]

As of September 30, 2012 and December 31, 2011, the Company’s intangible assets and related accumulated amortization consisted of the following (in thousands):



		September 30, 2012				December 31, 2011
	Useful Life	Gross	Accumulated Amortization		Net	Gross	Accumulated Amortization		Net
Customer list	10 years	$1,000.0	$(170.1)		$829.9	$1,000.0	$(95.1)		$904.9
Manufacturing technology	10 years	3,900.0	(663.4	)	3,236.6	3,900.0	(370.9	)	3,529.1
Tradename	10 years	800.0	(136.1	)	663.9	800.0	(76.2	)	723.8
In process R&D	Indefinite	9,400.0	—		9,400.0	9,400.0	—		9,400.0
VSEL patent rights	19 years	669.0	(167.3	)	501.7	669.0	(140.8	)	528.2
Total Intangible Assets		$15,769.0	$(1,136.9)		$14,632.1	$15,769.0	$(683.0)		$15,086.0

Schedule of Amortization Expense [Table Text Block]

Total intangible amortization expense was classified in the operating expense categories for the periods included below as follows (in thousands):



	Three Months Ended September 30,				Nine Months Ended September 30,
	2012		2011		2012		2011
Cost of revenue	$	97.5	$	135.0	$	292.5	$	376.5
Research and development	8.8		8.8		26.4		26.4
Selling, general and administrative	45.0		67.5		135.0		188.3
Total	$	151.3	$	211.3	$	453.9	$	591.2

- Definition

Tabular disclosure of goodwill by reportable segment and in total. Disclosure details may include, but are not limited to, the carrying amount of goodwill, goodwill acquired during the year, goodwill impairment losses recognized, goodwill written-off due to the sale of a business unit, goodwill not yet allocated, and any other changes to goodwill.

+ References + Details

Shareholders' Equity (Tables)

9 Months Ended

Sep. 30, 2012

Shareholders’ Equity [Abstract]

Schedule of Compensation Cost for Share-based Payment Arrangements, Allocation of Share-based Compensation Costs by Plan [Table Text Block]

The following table summarizes the components of share-based compensation expense for the three and nine months ended September 30, 2012 and 2011 (in thousands):



	Three Months Ended					Nine Months Ended
	September 30,					September 30,
	2012		2011			2012		2011
Cost of goods sold	$	19.8	$	26.0		$	120.1	$	71.2
Research and development	102.2		(116.8		)	362.4		500.8
Selling, general and administrative	1,794.2		1,598.6			4,988.7		7,592.8
Total share-based compensation expense	$	1,916.2	$	1,507.8		$	5,471.2	$	8,164.8

Schedule Of Share-Based Compensation, Stock Options and Warrants Activity [Table Text Block]

The following table summarizes the activity for stock options and warrants for the nine months ended September 30, 2012:



	Stock Options		Warrants
Outstanding at December 31, 2011	17,143,505		37,389,825

Changes during the Year:
Granted	7,167,029		30,400,525
Exercised	—		(10,160,521	)
Forfeited	(1,737,759	)	(3	)
Expired	(183,133	)	(1,315,644	)
Outstanding at September 30, 2012	22,389,642		56,314,182

Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]



	Stock Options		Warrants		Restricted Stock
Unrecognized compensation cost	$	2,179.9	$	94.9	$	130.6
Expected weighted-average period in years of compensation cost to be recognized	1.84		0.39		0.14

- Definition

Tabular disclosure of the allocation of equity-based compensation costs to a given line item on the balance sheet and income statement for the period. This may include the reporting line for the costs and the amount capitalized and expensed.

+ References + Details

Discontinued Operations (Tables)

9 Months Ended

Sep. 30, 2012

Balance Sheet [Member] | Regenerative Medicine - China segment [Member]

Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]

Schedule of Disposal Groups, Including Discontinued Operations, Income Statement, Balance Sheet and Additional Disclosures [Table Text Block]

The summary of the assets and liabilities related to Regenerative Medicine-China discontinued operations as of December 31, 2011 was as follows (in thousands):



	December 31, 2011
Assets:
Cash and cash equivalents	$	103.3
Prepaid expenses and other current assets	284.4
Property, plant and equipment, net	1,256.8
Other Assets	149.0
	$	1,793.5
Liabilities:
Accounts payable	$	177.8
Accrued liabilities	31.0
	$	208.8

Balance Sheet [Member] | Pharmaceutical Manufacturing - China business [Member]

Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]

Schedule of Disposal Groups, Including Discontinued Operations, Income Statement, Balance Sheet and Additional Disclosures [Table Text Block]



	September 30, 2012		December 31, 2011
Cash and cash equivalents	$	10,789.5	$	8,707.0
Restricted cash	2,892.4		—
Accounts receivable, net	7,105.3		5,525.7
Inventory	15,141.9		16,505.7
Deferred income taxes	344.2		463.7
Prepaid expenses and other current assets	750.9		777.5
Property, plant and equipment, net	37,327.3		36,490.4
Land use rights, net	3,021.5		4,872.4
Goodwill	—		8,495.7
Intangible assets, net	—		21,846.4
Other assets	2,821.1		2,459.9
Total assets	$	80,194.1	$	106,144.4

Accounts payable	$	8,730.5	$	7,950.3
Accrued liabilities	2,874.7		1,705.8
Bank loans	17,369.0		15,712.0
Notes payable	6,541.3		—
Income tax payable	2,142.3		621.6
Deferred income taxes	5,902.4		6,177.4
Unearned revenue	1,544.1		1,315.4
Amount due related parties	8,519.2		20,862.7
Total Liabilities	$	53,623.5	$	54,345.2

Income Statement [Member] | Regenerative Medicine - China segment [Member]

Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]

Schedule of Disposal Groups, Including Discontinued Operations, Income Statement, Balance Sheet and Additional Disclosures [Table Text Block]

As of March 31, 2012, the Company recognized the following loss on exit of the Regenerative Medicine-China business (in thousands):



Cash	$	195.1
Prepaid expenses and other current assets	14.9
Property, plant and equipment, net	1,023.7
Other Assets	330.5
Accounts payable	(177.1		)
Accrued liabilities	(79.2		)
Accumulated comprehensive income	(169.9		)
Loss on exit of segment	$	1,138.0

The operating results of the Regenerative Medicine – China business for the three and nine months ended September 30, 2012 and 2011, which are included in discontinued operations, were as follows (in thousands):



	Three Months Ended September 30,					Nine Months Ended September 30,
	2012		2011			2012			2011
Revenue	$	—	$	98.8		$	52.3		$	148.9
Cost of revenues	—		(31.3		)	(30.6		)	(49.4		)
Research and development	—		93.6			(103.3		)	(64.5		)
Selling, general, and administrative	—		(782.3		)	(497.3		)	(1,572.3		)
Other income (expense)	—		1.4			(6.8		)	(11.3		)
Loss on exit of segment	—		—			(1,138.0		)	—
Loss from discontinued operations	$	—	$	(619.8	)	$	(1,723.7	)	$	(1,548.6	)

Income Statement [Member] | Pharmaceutical Manufacturing - China business [Member]

Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]

Schedule of Disposal Groups, Including Discontinued Operations, Income Statement, Balance Sheet and Additional Disclosures [Table Text Block]

The operating results of the Pharmaceutical Manufacturing - China business for the three and nine months ended September 30, 2012 and 2011, including the estimated asset impairments based on the definitive agreement purchase price, were as follows (in thousands):



	Three Months Ended September 30,						Nine Months Ended September 30,
	2012			2011			2012			2011
Revenue	$	20,036.4		$	15,513.0		$	57,254.7		$	49,806.0
Cost of revenues	(11,551.5		)	(11,905.1		)	(37,131.5		)	(36,207.1		)
Research and development	(611.8		)	(782.5		)	(2,231.5		)	(1,885.3		)
Selling, general, and administrative	(3,514.7		)	(2,107.4		)	(9,714.8		)	(8,233.5		)
Other expense	(0.9		)	(583.2		)	(1,008.3		)	(949.3		)
Provision for income taxes	(1,029.9		)	(26.2		)	(1,535.4		)	(907.6		)
Asset impairments	(3,175.5		)	—			(31,170.1		)	—
(Loss) income from discontinued operations	$	152.1		$	108.6		$	(25,536.9	)	$	1,623.2

- Definition

Tabular disclosure of disposal groups, which may include the gain (loss) recognized in the income statement and the income statement caption that includes that gain (loss), amounts of revenues and pretax profit or loss reported in discontinued operations, the classification and carrying value of the assets and liabilities comprising the disposal group, and the segment in which the disposal group was reported. Also may include the amount of adjustments to amounts previously reported in discontinued operations such as resolution of contingencies arising from the disposal transaction or the operations of the component prior to disposal.

+ References + Details

Commitments and Contingencies (Tables)

9 Months Ended

Sep. 30, 2012

Commitments and Contingencies [Abstract]

Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]

A summary of future minimum rental payments required under operating leases that have initial or remaining terms in excess of one year as of September 30, 2012 are as follows (in thousands):



Years ended	Operating Leases
2012	$	410.8
2013	1,226.5
2014	962.1
2015	739.2
2016	563.9
Thereafter	293.2
Total minimum lease payments	$	4,195.7

The Business (Details) - segment			9 Months Ended
The Business (Details) - segment	Jun. 19, 2012	Jun. 18, 2012	Sep. 30, 2012
The Company [Line Items]
Segment Reporting, Additional Information about Entity's Reportable Segments		three reportable segments
Number of Reporting Segments	1	3
Erye Sale Agreement [Member]
The Company [Line Items]
Sale of Stock, Percentage of Ownership before Transaction			51.00%

The Business Principal of consolidation (Details)

9 Months Ended

Sep. 30, 2012

NeoStem Therapies, Inc [Member] | UNITED STATES

Schedule of Subisidiary [Line Items]

Subsidiary, Ownership Interest by Parent

100.00%

Stem Cell Technologies, Inc [Member] | UNITED STATES

Schedule of Subisidiary [Line Items]

Subsidiary, Ownership Interest by Parent

100.00%

Amorcyte, LLC [Member] | UNITED STATES

Schedule of Subisidiary [Line Items]

Subsidiary, Ownership Interest by Parent

100.00%

CBH Acquisition LLC [Member] | UNITED STATES

Schedule of Subisidiary [Line Items]

Subsidiary, Ownership Interest by Parent

100.00%

China Biopharmaceuticals Holdings, Inc. [Member] | UNITED STATES

Schedule of Subisidiary [Line Items]

Subsidiary of Limited Liability Company or Limited Partnership, Ownership Interest

100.00%

Suzhou Erye Pharmaceuticals Company Ltd. [Member] | CHINA

Schedule of Subisidiary [Line Items]

Subsidiary of Limited Liability Company or Limited Partnership, Ownership Interest

51.00%

^[1]

Progenitor Cell Therapy, LLC [Member] | UNITED STATES

Schedule of Subisidiary [Line Items]

Subsidiary, Ownership Interest by Parent

100.00%

NeoStem Family Storage, LLC [Member] | UNITED STATES

Schedule of Subisidiary [Line Items]

Subsidiary of Limited Liability Company or Limited Partnership, Ownership Interest

100.00%

Athelos Corporation [Member] | UNITED STATES

Schedule of Subisidiary [Line Items]

Subsidiary of Limited Liability Company or Limited Partnership, Ownership Interest

80.10%

PCT Allendale, LLC [Member] | UNITED STATES

Schedule of Subisidiary [Line Items]

Subsidiary of Limited Liability Company or Limited Partnership, Ownership Interest

100.00%

[1]	Represents the operations of our former Pharmaceutical Manufacturing - China reporting segment, which was discontinued on June 18, 2012, and is currently reported in discontinued operations. The Erye divestiture closed on November 13, 2012 (see Note 16).

Summary of Significant Accounting Policies (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2012	Sep. 30, 2011	Sep. 30, 2012	Sep. 30, 2011
Summary of Significant Accounting Policies [Abstract]
Clinical Services Reimbursement	$ 0.9	$ 0.7	$ 2.9	$ 1.8
Revene Recognition Period for Cryoperservation Process			24 hours

Acquisitions Fair value of assets acquired and liabilities (Details) - USD ($)	12 Months Ended
	Dec. 31, 2011	Sep. 30, 2012	Oct. 17, 2011
Business Acquisition [Line Items]
Goodwill	$ 11,117,770	$ 11,117,770
Deferred Tax Liability	$ 3,774,655	$ 3,774,655
Amorcyte Acquisition [Member]
Business Acquisition [Line Items]
Business Acquisition, Name of Acquired Entity	Amo Acquisition Company I, Inc.
Cash			$ 92,900
Prepaid Expenses			178,200
In Process R&D			9,400,000
Goodwill			4,104,500
Accounts Payable & Accrued Liabilities			1,177,100
Deferred Tax Liability			3,774,700
Amount Due Related Party			$ 340,400

Cash and Cash Equivalents (Details) - USD ($)	Sep. 30, 2012	Dec. 31, 2011	Sep. 30, 2011
Cash and Cash Equivalents [Abstract]
Cash and cash equivalents	$ 5,390,611	$ 3,935,160	$ 10,164,987
Cash, FDIC Insured Amount	$ 600,000	$ 800,000

- Definition

Includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the Entity may deposit additional funds at any time and also effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Compensating balance arrangements that do not legally restrict the withdrawal or usage of cash amounts may be reported as Cash and Cash Equivalents, while legally restricted deposits held as compensating balances against borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits are not generally reported as cash and cash equivalents. Includes cash and cash equivalents associated with the entity's continuing operations. Excludes cash and cash equivalents associated with the disposal group (and discontinued operation).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 95
-Paragraph 8, 9
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 02
-Paragraph 1
-Article 5

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 95
-Paragraph 7
-Footnote 1
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 95
-Paragraph 7, 26
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Cash
-URI http://asc.fasb.org/extlink&oid=6506951

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Cash Equivalents
-URI http://asc.fasb.org/extlink&oid=6507016

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.1)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6361293&loc=d3e6676-107765

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3044-108585

+ Details

Inventories (Details) - USD ($)	Sep. 30, 2012	Dec. 31, 2011
Deferred Revenue Arrangement [Line Items]
Inventory, Net	$ 448,045	$ 647,745
Multiple Stage Contracts [Member]
Deferred Revenue Arrangement [Line Items]
Deferred Revenue	$ 600,000	$ 1,000,000

Loss Per Share (Details) - shares	9 Months Ended
Loss Per Share (Details) - shares	Sep. 30, 2012	Sep. 30, 2011
Stock Options [Member]
Class of Stock [Line Items]
Dilutive Securities Excluded From Computation Of Earnings Per Share, Shares	22,389,642	17,749,895
Warrants [Member]
Class of Stock [Line Items]
Dilutive Securities Excluded From Computation Of Earnings Per Share, Shares	56,314,182	35,208,817
Series E Preferred Stock [Member]
Class of Stock [Line Items]
Dilutive Securities Excluded From Computation Of Earnings Per Share, Shares	2,634,799	4,693,730
Restricted Stock [Member]
Class of Stock [Line Items]
Dilutive Securities Excluded From Computation Of Earnings Per Share, Shares	232,000	830,834

Fair Value Measurements (Details)	3 Months Ended
Fair Value Measurements (Details)	Sep. 30, 2012
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Fair Value, Debt Instrument, Valuation Techniques	The fair value of contingent consideration obligations is based on a discounted cash flow model using a probability-weighted income approach
contingent cosideration [Member]
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Fair Value Inputs Discount Rate	30.00%

Fair Value Measurements Fair value hierarchy the Company’s financial assets and liabilities (Details) - USD ($)	Sep. 30, 2012	Dec. 31, 2011
Fair Value, Inputs, Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Money market investments	$ 2,500,100	$ 2,497,400
Embedded derivative liabilities	0	0
Warrant Derivative Liabilities	0	0
Contingent Consideration Classified As Equity Fair Value Disclosure	0	0
Fair Value, Inputs, Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Money market investments	0	0
Embedded derivative liabilities	0	0
Warrant Derivative Liabilities	0	0
Contingent Consideration Classified As Equity Fair Value Disclosure	0	0
Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Money market investments	0	0
Embedded derivative liabilities	257,000	391,700
Warrant Derivative Liabilities	170,600	82,700
Contingent Consideration Classified As Equity Fair Value Disclosure	$ 3,130,000	$ 3,130,000

Fair Value Measurements Financial instruments with significant Level 3 inputs (Details) - USD ($)	3 Months Ended	9 Months Ended
	Sep. 30, 2012	Sep. 30, 2012
Derivative Financial Instruments, Liabilities [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Begining liability balance	$ 263,200	$ 391,700
Change in fair value recorded in earnings	(6,200)	(134,700)
Begining liability balance	257,000	257,000
Warrants [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Begining liability balance	99,800	82,700
Change in fair value recorded in earnings	70,800	87,900
Begining liability balance	$ 170,600	$ 170,600

Goodwill and Other Intangible Assets Goodwill (Details)	Sep. 30, 2012 USD ($)
Goodwill [Roll Forward]
Goodwill, as of December 31, 2011	$ 11,117,770
Goodwill, as of June 30, 2012	$ 11,117,770

- Definition

Carrying amount as of the balance sheet date, which is the cumulative amount paid and (if applicable) the fair value of any noncontrolling interest in the acquiree, adjusted for any amortization recognized prior to the adoption of any changes in generally accepted accounting principles (as applicable) and for any impairment charges, in excess of the fair value of net assets acquired in one or more business combination transactions.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 142
-Paragraph 45
-Subparagraph e
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 142
-Paragraph 43
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 141R
-Paragraph 68
-Subparagraph l
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6388280&loc=d3e13770-109266

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6905597&loc=d3e13816-109267

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 141R
-Paragraph 72
-Subparagraph d
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 142
-Paragraph 45
-Subparagraph e
-Clause 1
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 141R
-Paragraph 34
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Goodwill and Other Intangible Assets Intangible Assets and Related Accumulated Amortization (Details) - USD ($)	9 Months Ended
	Sep. 30, 2012	Dec. 31, 2011
Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Gross	$ 15,769,000	$ 15,769,000
Finite-Lived Intangible Assets, Accumulated Amortization	(1,136,900)	(683,000)
Finite-Lived Intangible Assets, Net	14,632,100	15,086,000
Customer Lists [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Gross	1,000,000	1,000,000
Finite-Lived Intangible Assets, Accumulated Amortization	(170,100)	(95,100)
Finite-Lived Intangible Assets, Net	$ 829,900	904,900
Finite-Lived Intangible Assets, Useful Life	10 years
Manufacturing Technology [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Gross	$ 3,900,000	3,900,000
Finite-Lived Intangible Assets, Accumulated Amortization	(663,400)	(370,900)
Finite-Lived Intangible Assets, Net	$ 3,236,600	3,529,100
Finite-Lived Intangible Assets, Useful Life	10 years
Trade Names [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Gross	$ 800,000	800,000
Finite-Lived Intangible Assets, Accumulated Amortization	(136,100)	(76,200)
Finite-Lived Intangible Assets, Net	$ 663,900	723,800
Finite-Lived Intangible Assets, Useful Life	10 years
In Process R&D [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Gross	$ 9,400,000	9,400,000
Finite-Lived Intangible Assets, Accumulated Amortization	0	0
Finite-Lived Intangible Assets, Net	$ 9,400,000	9,400,000
Finite Lived Intangible Assets, Useful Life [String]	Indefinite
VSEL Patent Rights [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Gross	$ 669,000	669,000
Finite-Lived Intangible Assets, Accumulated Amortization	(167,300)	(140,800)
Finite-Lived Intangible Assets, Net	$ 501,700	$ 528,200
Finite-Lived Intangible Assets, Useful Life	19 years

Goodwill and Other Intangible Assets Intangible Amortization Expense (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2012	Sep. 30, 2011	Sep. 30, 2012	Sep. 30, 2011
Intangible Asset Amortization Expense By Category [Line Items]
Amortization of Intangible Assets	$ 151,300	$ 211,300	$ 453,900	$ 591,200
Cost of Revenue [Member]
Intangible Asset Amortization Expense By Category [Line Items]
Amortization of Intangible Assets	97,500	135,000	292,500	376,500
Research and Development Expense [Member]
Intangible Asset Amortization Expense By Category [Line Items]
Amortization of Intangible Assets	8,800	8,800	26,400	26,400
General and Administrative Expense [Member]
Intangible Asset Amortization Expense By Category [Line Items]
Amortization of Intangible Assets	$ 45,000	$ 67,500	$ 135,000	$ 188,300

Debt (Details) - USD ($)			9 Months Ended
Debt (Details) - USD ($)	Dec. 06, 2010	Oct. 31, 2007	Sep. 30, 2012	Dec. 31, 2011
Debt Instrument [Line Items]
Notes Payable			$ 183,500	$ 148,100
Convertible Notes Payable [Member]
Debt Instrument [Line Items]
Subordinated Notes to Finance Leveraged Buyout		$ 3,120,000
Purchase of condominium units		$ 3,818,500
Debt Instrument, Duration of Payments (in months)		239 months
Debt Instrument, Frequency of Periodic Payment		monthly payments
Debt Instrument, Amortization Period (in years)		20 years
Debt Instrument, Periodic Payment			$ 20,766
Debt Instrument, Periodic Payment, Interest			5.00%
Debt Instrument, Collateral, Debt Service Period Held in Escrow (in months)		18 months
Debt Instrument, Maturity Date			Oct. 01, 2027
Debt Instrument, Call Date, Earliest			Oct. 01, 2017
Mortgage Loans on Real Estate, Carrying Amount of Mortgages			$ 2,622,900
Mortgage Loan Repayble Amount within 12 months			118,400
PCT Allendale, LLC [Member] \| Convertible Notes Payable [Member]
Debt Instrument [Line Items]
Subordinated Notes to Finance Leveraged Buyout	$ 1,000,000
Debt Instrument, Periodic Payment, Interest	6.00%
Mortgage Loans on Real Estate, Carrying Amount of Mortgages			870,800
Mortgage Loan Repayble Amount within 12 months			$ 87,100
Debt Instrument, Period of Loan (in months)	124 months
Debt Instrument, Period of Fixed Interest Rate (in months)	64 months
Debt Instrument, Period of Interest Only Payments (in months)	4 months
Minimum [Member]
Debt Instrument [Line Items]
Debt Instrument, Maturity Term (in years)			1 year
Maximum [Member]
Debt Instrument [Line Items]
Debt Instrument, Maturity Term (in years)			5 years

Preferred Stock (Details) - USD ($)		3 Months Ended		9 Months Ended
Preferred Stock (Details) - USD ($)	Nov. 19, 2010	Sep. 30, 2012	Sep. 30, 2011	Sep. 30, 2012	Sep. 30, 2011	Jun. 30, 2012	Dec. 31, 2011
Class of Stock [Line Items]
Preferred Offering Units	10,582,011
Preferred Stock, Par or Stated Value Per Share	$ 0.01	$ 0.01		$ 0.01			$ 0.01
Sale of Stock, Price Per Share	$ 0.945
Proceeds from Issuance or Sale of Equity				$ 12,160,227	$ 21,167,682
Common Stock Dividends, Shares				7,950,107
Preferred Stock, pre-payment, Minimum Increment Value		$ 1,000,000		$ 1,000,000
Preferred Stock, Pre-payment Option, Percent of Outstanding Balance				110.00%
Preferred Stock, Pre-payment Option, Minimum Number of Days Notice to Pre-pay				30 days
Preferred Offering, Maximum Period of Escrow of Proceeds	2 years 6 months
Preferred Stock Conversion, Conversion Price per share						$ 2.0004
Adjusted Conversion Price						$ 1.18
Increase (Decrease) in Fair Value of Interest Rate Fair Value Hedging Instruments		$ (6,200)	$ 70,800	$ (134,800)	$ 87,900
Series E Seven Percent Senior Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Percent of Preferred Shares Required to be Redeemed Monthly				3.70%
Number of Shares of Preferred Stock Included in Preferred Offering Unit	1
Preferred Stock, Dividend Rate, Percentage	7.00%
Warrant to purchase 0.25 of a share of Common Stock [Member]
Class of Stock [Line Items]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	0.25
Stock and Warrants Issued During Period, Shares, Preferred Stock and Warrants	1,322,486	1,747,188		1,747,188
Preferred Offering Unit [Member]
Class of Stock [Line Items]
Proceeds from Issuance or Sale of Equity	$ 10,000,000
Net Proceeds from Issuance or Sale of Equity	8,876,700
Escrow Deposit	$ 2,500,000
Warrant to purchase 0.0155 of a share of Common Stock [Member]
Class of Stock [Line Items]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	0.0155
Stock and Warrants Issued During Period, Shares, Preferred Stock and Warrants	164,418
Preferred Stock [Member]
Class of Stock [Line Items]
Fair value of Equity						$ 2,721,100
Embedded Derivative Financial Instruments [Member]
Class of Stock [Line Items]
Fair value of Equity						257,000
Warrant [Member]
Class of Stock [Line Items]
Fair value of Equity						$ 170,600

Shareholders' Equity (Details)		1 Months Ended				3 Months Ended		9 Months Ended
Shareholders' Equity (Details)	Sep. 30, 2012 USD ($) $ / shares $ / warrant shares	Aug. 31, 2012 USD ($) $ / shares $ / warrant shares	Jul. 31, 2012 USD ($) $ / warrant shares	Apr. 30, 2012 USD ($) shares	Mar. 31, 2012 USD ($) $ / shares $ / warrant shares	Sep. 30, 2012 USD ($) $ / shares $ / warrant shares	Sep. 30, 2011 USD ($)	Sep. 30, 2012 USD ($) $ / shares $ / warrant shares	Sep. 30, 2011 USD ($)	Dec. 31, 2011 $ / shares	Dec. 31, 2009 $ / warrant
Class of Stock [Line Items]
Stock Issued During Period, Shares, Restricted Stock Award, Gross								2,649,236
Common Stock, Par or Stated Value Per Share \| $ / shares	$ 0.001					$ 0.001		$ 0.001		$ 0.001
Proceeds from Warrant Exercises \| $								$ 5,925,931	$ 0
Warrant Inducements \| $						$ 1,012,819	$ 0	$ 1,012,819	$ 0
Underwriting Offering [Member]
Class of Stock [Line Items]
Stock Issued During Period, Shares, New Issues				2,000,000	15,000,000
Common Stock, Par or Stated Value Per Share \| $ / shares					$ 0.40
Number of Shares of Common Stock Per Unit					1
Warrant Expiration Period					5 years
Class of Warrant or Right, Exercise Price of Warrants or Rights \| $ / warrant	0.51		0.51		0.51	0.51		0.51
Proceeds from Warrant Exercises \| $	$ 700,000		$ 1,600,000
Proceeds from Issuance of Common Stock Gross \| $				$ 800,000	$ 6,000,000
Proceeds from Issuance of Common Stock Net \| $				$ 744,000	$ 5,297,000
Class of Warrant or Right, Additional Number of Securities Called by Warrants or Rights	1,457,212					1,457,212		1,457,212
Exercise of Warrants Issued			3,150,344
Warrant Inducements \| $						$ 0
Warrant Inducement Per Share \| $ / shares	$ 0.03
Common Stock [Member]
Class of Stock [Line Items]
Stock Issued During Period, Shares, New Issues								28,765,623
Warrant inducements (in shares)								1,458,952
2009 Equity Plan [Member]
Class of Stock [Line Items]
Shares Issued in Period								1,039,339
July 2012 New Warrant [Member]
Class of Stock [Line Items]
Shares Issued in Lieu of Cash Compensation								398,115
Aspire Capital Purchase Agreement [Member]
Class of Stock [Line Items]
Warrant Expiration Period		5 years
Class of Warrant or Right, Exercise Price of Warrants or Rights \| $ / warrant		0.60
Extension of term of purchase agreement (in months)		24 months
May-July 2012 private placement warrants [Member]
Class of Stock [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights \| $ / warrant			0.51
Proceeds from Warrant Exercises \| $			$ 1,400,000
Exercise of Warrants Issued			2,808,140
Warrant holder A [Member]
Class of Stock [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights \| $ / warrant		0.51									2.50
Warrant Inducements \| $						200,000
Class of Warrant or Right, Number of Securities Called by Warrants or Rights		2,100,000
Proceeds from Issuance of Warrants \| $		$ 1,100,000
Warrant holder B [Member]
Class of Stock [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights \| $ / warrant		1.85
Class of Warrant or Right, Additional Number of Securities Called by Warrants or Rights		300,000
Warrant Inducements \| $						400,000
Class of Warrant or Right, Number of Securities Called by Warrants or Rights		344,825
Exercise price of Warrants \| $ / shares		$ 1.45
Proceeds from Issuance of Warrants \| $		$ 1,100,000
Warrant inducements (in shares)		1,458,952
July 2012 New Warrant [Member]
Class of Stock [Line Items]
Warrant Expiration Period			5 years
Warrant Inducements \| $						$ 400,000
Private Placement [Member]
Class of Stock [Line Items]
Stock Issued During Period, Shares, New Issues								11,800,000
Proceeds from Warrant Exercises \| $								$ 6,100,000
Warrants Issued During Period								8,300,000
Minimum [Member] \| July 2012 New Warrant [Member]
Class of Stock [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights \| $ / warrant			0.66
Minimum [Member] \| Private Placement [Member]
Class of Stock [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights \| $ / warrant	0.51					0.51		0.51
Maximum [Member] \| July 2012 New Warrant [Member]
Class of Stock [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights \| $ / warrant			0.69
Maximum [Member] \| Private Placement [Member]
Class of Stock [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights \| $ / warrant	0.74					0.74		0.74
Common Stock [Member] \| Aspire Capital Purchase Agreement [Member]
Class of Stock [Line Items]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights		1,612,903

Shareholders' Equity Components of share-based compensation expense (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2012	Sep. 30, 2011	Sep. 30, 2012	Sep. 30, 2011
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Expense	$ 1,916,200	$ 1,507,800	$ 5,471,200	$ 8,164,800
Cost of Sales [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Expense	19,800	26,000	120,100	71,200
Research and Development Expense [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Expense	102,200	(116,800)	362,400	500,800
General and Administrative Expense [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Expense	$ 1,794,200	$ 1,598,600	$ 4,988,700	$ 7,592,800

- Definition

Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.

+ References + Details

Shareholders' Equity Activity for stock options and warrants (Details)	9 Months Ended
	Sep. 30, 2012 shares
Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options and Non-Option Equity Instruments, Outstanding [Roll Forward]
Stock Options, Outstanding at December 31, 2011	17,143,505
Stock Options Granted	7,167,029
Stock Options Exercised	0
Stock Options Forfeited	(1,737,759)
Stock Options Expired	(183,133)
Stock Options, Outstanding at September 30, 2012	22,389,642
Warrants [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options and Non-Option Equity Instruments, Outstanding [Roll Forward]
Warrants, Outstanding at December 31, 2011	37,389,825
Warrants Granted	30,400,525
Warrants Exercised	(10,160,521)
Warrants Forfeited	(3)
Warrants Expired	(1,315,644)
Warrants, Outstanding at September 30, 2012	56,314,182

Shareholders' Equity Total compensation cost related to nonvested awards (Details)	9 Months Ended
	Sep. 30, 2012 yr	Jun. 30, 2012 USD ($)
Restricted Stock [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Unrecognized compensation cost \| $		$ 130,600
Excepted weighted-average period in years of compensation cost to be recognized \| yr	0.14
Warrants [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Unrecognized compensation cost \| $		94,900
Excepted weighted-average period in years of compensation cost to be recognized \| yr	0.39
Stock Option [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Unrecognized compensation cost \| $		$ 2,179,900
Excepted weighted-average period in years of compensation cost to be recognized \| yr	1.84

Income Taxes (Details)	Dec. 31, 2011 USD ($)
Income Taxes [Abstract]
Unrecognized Tax Benefits Resulting in Net Operating Loss Carryforward	$ 25,994,800
Unrecognized Tax Benefits Resulting in Net Operating Loss Carryforward	8,838,200
Operating Loss Carryforwards	$ 47,427,300

- Definition

Amount of an unrecognized tax benefit that is directly related to a position taken in a tax year that results in a net operating loss carryforward. This amount is presented as a reduction of the related deferred tax asset in the balance sheet if that deferred tax asset is not used. This amount is presented separately from the deferred tax asset for a net operating loss carryforward if this unrelated tax benefit is associated with a different tax position.

+ References + Details

Discontinued Operations (Details)			1 Months Ended						3 Months Ended	9 Months Ended			12 Months Ended
Discontinued Operations (Details)	Nov. 13, 2012 shares	Sep. 30, 2012 USD ($)	Aug. 31, 2012 USD ($)	Jul. 31, 2012 CNY (¥)	Jul. 31, 2012 USD ($)	Jul. 31, 2011 CNY (¥)	Apr. 30, 2011 USD ($)	Jan. 31, 2011 USD ($)	Sep. 30, 2012 USD ($)	Sep. 30, 2012 CNY (¥)	Sep. 30, 2012 USD ($)	Sep. 30, 2011 USD ($)	Dec. 31, 2011 USD ($)	Dec. 31, 2009	Jun. 30, 2012	Jun. 18, 2012 USD ($)	Oct. 31, 2009
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Equity Method Investment, Ownership Percentage															51.00%		51.00%
Disposal Group, Including Discontinued Operation, Cash and Cash Equivalents		$ 10,789,480							$ 10,789,480		$ 10,789,480	$ 1,548,351
Cash received in divestiture											$ 2,728,000	0
Percentage of Registered Capital		50.00%							50.00%		50.00%
Annual Appropriation, Percent		10.00%							10.00%		10.00%
Deposit Liabilities, Accrued Interest											$ 1,655,600	$ 1,238,400
Percentage of Undistributed Profit																	49.00%
Percentage of Additional Paid-In Capital																	45.00%
Percentage of Distributed Profit																	6.00%
Bank Deposit Freeze \| ¥				¥ 50,000,000
Pharmaceutical Manufacturing - China business [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Disposal Group, Including Discontinued Operation, Cash and Cash Equivalents		$ 10,789,500							$ 10,789,500		10,789,500		$ 8,707,000
Pharmaceutical Manufacturing - China business [Member] \| Equity Purchase Agreement [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Disposal Group, Including Discontinued Operation, Cash and Cash Equivalents																$ 12,300,000
Proceeds from Divestiture of Business, Percent of Total Cash Purchase Price		50.00%	40.00%	10.00%	10.00%
Release of Escrow of Offshore Second Purchase Price Payment		$ 1,500,000
Escrow Deposit of Offshore Second Purchase Price Payment			$ 2,456,000
Escrow Deposit of Onshore Second Purchase Price Payment		6,140,000	2,456,000
Cash received in divestiture		2,728,000
Proceeds from Divestiture of Businesses and Interests in Affiliates			$ 4,912,000		$ 1,228,000
Erye's [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Due to Related Parties		8,500,000							8,500,000		$ 8,500,000		$ 20,900,000
Related Party Transaction, Rate										6.00%	6.00%		6.56%
Deposit Liabilities, Accrued Interest									700,000
Payment of loan principal									11,600,000
Dividends, Common Stock							$ 10,259,700	$ 13,671,100
Dividends Distributed to Related Party							5,027,300	6,698,800
Adjustments To Additional Paid In Capital re-invested amount							$ 5,232,400	$ 6,972,300
Payments Related to Tax Withholding for Share-based Compensation													10.00%
Tax Withholding Amount													$ 1,220,500
PRC Subsidiary [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Statutory reserves		2,479,500							2,479,500		$ 2,479,500		2,488,000
Amount of Restricted Net Assets for Consolidated and Unconsolidated Subsidiaries		$ 186,800							$ 186,800		186,800		$ 185,000
Case 1 [Member] \| Welman vs. Erye Member [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Loss Contingency, Damages Awarded, Value														50000
Case 2 [Member] \| Welman vs. Erye Member [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Bank Deposit Freeze										¥ 17,900,000	$ 2,800,000
Case 3 [Member] \| Welman vs. Erye Member [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Bank Deposit Freeze \| ¥						¥ 2,000,000				¥ 1,000,000
Erye's [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Equity Method Investment, Ownership Percentage																51.00%
Term of Joint Venture Distribution Rule																	3 years
Erye Merger Agreement [Member] \| Erye's [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners		49.00%							49.00%		49.00%
Sale [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Divestiture, common stock returned \| shares	1,040,000
Divestiture, cancellation of options \| shares	1,170,000
Divestiture, cancellation of common stock warrants \| shares	640,000

Discontinued Operations Company recognized loss on exit (Details) - Regenerative Medicine - China segment [Member]	1 Months Ended
	Mar. 31, 2012 USD ($)
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Loss on exit of segment	$ 1,138,000
Gain (Loss) on Dispostion of Cash and Cash Equivalents [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Loss on exit of segment	195,100
Gain (Loss) on Disposition of Prepaid Expenses and Other Current Assets [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Loss on exit of segment	14,900
Gain (Loss) on Disposition of Property, Plant and Equipment, Net [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Loss on exit of segment	1,023,700
Gain (Loss) on Disposition of Other Assets [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Loss on exit of segment	330,500
Gain (Loss) on Disposition of Accounts Payable [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Loss on exit of segment	(177,100)
Gain (Loss) on Disposition of Accrued Liabilities [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Loss on exit of segment	(79,200)
Gain (Loss) on Disposition of Accumulated Comprehensive Income [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Loss on exit of segment	$ (169,900)

Discontinued Operations The operating results of the Regenerative Medicine – China business (Details) - Regenerative Medicine - China segment [Member] - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2012	Sep. 30, 2011	Sep. 30, 2012	Sep. 30, 2011
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Disposal Group, Including Discontinued Operation, Revenue	$ 0	$ 98,800	$ 52,300	$ 148,900
Disposal Group, Including Discontinued Operation, Costs of Goods Sold	0	(31,300)	(30,600)	(49,400)
Disposal Group Including Discontinued Operation Research and Development	0	93,600	(103,300)	(64,500)
Disposal Group Including Discontinued Operation Selling General and Administrative	0	(782,300)	(497,300)	(1,572,300)
Disposal Group, Including Discontinued Operation, Operating Expense	0	1,400	(6,800)	(11,300)
Loss on Exit of Segment	0	0	(1,138,000)	0
Disposal Group, Including Discontinued Operation, Operating Income (Loss)	$ 0	$ (619,800)	$ (1,723,700)	$ (1,548,600)

Discontinued Operations The summary of assets and liabilities related to Regenerative Medicine - China business (Details) - USD ($)	Sep. 30, 2012	Dec. 31, 2011	Sep. 30, 2011
Assets:
Cash and cash equivalents	$ 10,789,480		$ 1,548,351
Regenerative Medicine - China segment [Member]
Assets:
Cash and cash equivalents		$ 103,300
Prepaid expenses and other current assets		284,400
Property, plant and equipment, net		1,256,800
Other assets		149,000
Assets of Disposal Group, Including Discontinued Operation		1,793,500
Liabilities:
Accounts Payable		177,800
Accrued liabilities		31,000
Liabilities of Disposal Group, Including Discontinued Operation		$ 208,800

Discontinued Operations The operating results of pharmaceutical manufacturing - China business (Details) - Pharmaceutical Manufacturing - China business [Member] - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2012	Sep. 30, 2011	Sep. 30, 2012	Sep. 30, 2011
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Disposal Group, Including Discontinued Operation, Revenue	$ 20,036,400	$ 15,513,000	$ 57,254,700	$ 49,806,000
Disposal Group, Including Discontinued Operation, Costs of Goods Sold	(11,551,500)	(11,905,100)	(37,131,500)	(36,207,100)
Disposal Group Including Discontinued Operation Research and Development	(611,800)	(782,500)	(2,231,500)	(1,885,300)
Disposal Group Including Discontinued Operation Selling General and Administrative	(3,514,700)	(2,107,400)	(9,714,800)	(8,233,500)
Disposal Group, Including Discontinued Operation, Operating Expense	(900)	(583,200)	(1,008,300)	(949,300)
Discontinued Operation, Provision for Loss (Gain) on Disposal, before Income Tax	(1,029,900)	(26,200)	(1,535,400)	(907,600)
Disposal Group Including Discontinued Operation Assets Impairment	(3,175,500)	0	(31,170,100)	0
Disposal Group, Including Discontinued Operation, Operating Income (Loss)	$ 152,100	$ 108,600	$ (25,536,900)	$ 1,623,200

Discontinued Operations The summary of the assets and liabilities related to Pharmaceutical Manufacturing- China discontinued operations (Details) - USD ($)	Sep. 30, 2012	Dec. 31, 2011	Sep. 30, 2011
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Cash and cash equivalents	$ 10,789,480		$ 1,548,351
Pharmaceutical Manufacturing - China business [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Cash and cash equivalents	10,789,500	$ 8,707,000
Restricted cash	2,892,400	0
Accounts receivable, net	7,105,300	5,525,700
Inventory	15,141,900	16,505,700
Deferred income taxes	344,200	463,700
Prepaid expenses and other current assets	750,900	777,500
Property, plant and equipment, net	37,327,300	36,490,400
Land use rights, net	3,021,500	4,872,400
Goodwill	0	8,495,700
Intangible assets, net	0	21,846,400
Other assets	2,821,100	2,459,900
Total assets	80,194,100	106,144,400
Accounts Payable	8,730,500	7,950,300
Accrued liabilities	2,874,700	1,705,800
Bank loans	17,369,000	15,712,000
Notes payable	6,541,300	0
Income tax payable	2,142,300	621,600
Deferred income taxes	5,902,400	6,177,400
Unearned revenue	1,544,100	1,315,400
Amount due related parties	8,519,200	20,862,700
Total Liabilities	$ 53,623,500	$ 54,345,200

Related Party Transactions (Details) - Equity Purchase Agreement [Member]	Jun. 18, 2012
CBH Acquisition LLC [Member]
Related Party Transaction [Line Items]
Noncontrolling Interest, Ownership Percentage by Parent	51.00%
EET and Fullbright [Member]
Related Party Transaction [Line Items]
Noncontrolling Interest, Ownership Percentage by Parent	49.00%

Commitments and Contingencies (Details) - USD ($)	1 Months Ended	3 Months Ended		9 Months Ended
Commitments and Contingencies (Details) - USD ($)	Aug. 31, 2012	Sep. 30, 2012	Sep. 30, 2011	Sep. 30, 2012	Sep. 30, 2011
Commitments and Contingencies [Abstract]
Base Monthly Rent Expense of Executive Offices	$ 27,000
Base Monthly Rent Expense of Subleases	$ 7,500
Operating Leases, Future Minimum Payments Due [Abstract]
2012		$ 410,800		$ 410,800
2013		1,226,500		1,226,500
2014		962,100		962,100
2015		739,200		739,200
2016		563,900		563,900
Thereafter		293,200		293,200
Total minimum lease payments		4,195,700		4,195,700
Operating Leases, Rent Expense		$ 377,300	$ 434,600	$ 1,225,500	$ 1,376,100

Subsequent Events (Details)								1 Months Ended						9 Months Ended
Subsequent Events (Details)	Nov. 13, 2012 USD ($) shares	Nov. 07, 2012 USD ($) $ / shares shares	Oct. 25, 2012 USD ($) $ / shares shares	Oct. 10, 2012 USD ($) $ / shares $ / warrant shares	Sep. 30, 2012 USD ($) $ / shares $ / warrant shares	Aug. 23, 2012 USD ($)	Nov. 19, 2010 $ / shares	Nov. 12, 2012 USD ($) shares	Oct. 31, 2012 USD ($) $ / shares $ / warrant shares	Aug. 31, 2012 USD ($) $ / warrant shares	Jul. 31, 2012 USD ($) $ / warrant	Apr. 30, 2012 shares	Mar. 31, 2012 $ / warrant shares	Sep. 30, 2012 USD ($) $ / shares $ / warrant shares	Sep. 30, 2011 USD ($)	Jun. 30, 2012	Dec. 31, 2011 $ / shares shares	Dec. 31, 2009 $ / warrant	Oct. 31, 2009
Subsequent Event [Line Items]
Proceeds from Warrant Exercises														$ 5,925,931	$ 0
Preferred stock, par value \| $ / shares					$ 0.01		$ 0.01							$ 0.01			$ 0.01
Common Stock, Shares, Issued \| shares					155,141,086									155,141,086			109,329,587
Sale of Stock, Price Per Share \| $ / shares							$ 0.945
Stock Issued During Period, Value, New Issues														$ 12,160,227
Equity Method Investment, Ownership Percentage																51.00%			51.00%
Sale [Member]
Subsequent Event [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period \| shares	1,170,000
Warrant holder A [Member]
Subsequent Event [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights \| $ / warrant										0.51								2.50
Class of Warrant or Right, Number of Securities Called by Warrants or Rights \| shares										2,100,000
Proceeds from Issuance of Warrants										$ 1,100,000
Warrant holder A [Member] \| Warranty Exercises [Member]
Subsequent Event [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights \| $ / warrant				1.45
Class of Warrant or Right, Number of Securities Called by Warrants or Rights \| shares				225,000
Proceeds from Issuance of Warrants				$ 326,250
Inducement Fee Calculation, Per Share Market Price \| $ / shares				$ 0.72
Underwriting Offering [Member]
Subsequent Event [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights \| $ / warrant					0.51						0.51		0.51	0.51
Proceeds from Warrant Exercises					$ 700,000						$ 1,600,000
Warrant Inducement Per Share \| $ / shares					$ 0.03
Stock Issued During Period, Shares, New Issues \| shares												2,000,000	15,000,000
Underwriting Offering [Member] \| Warranty Exercises [Member]
Subsequent Event [Line Items]
Warrants Exercised \| shares									690,311
Class of Warrant or Right, Exercise Price of Warrants or Rights \| $ / warrant									0.51
Proceeds from Warrant Exercises									$ 352,000
Warrant Inducement Per Share \| $ / shares									$ 0.03
Series E Seven Percent Senior Convertible Preferred Stock [Member]
Subsequent Event [Line Items]
Preferred Stock, Dividend Rate, Percentage							7.00%
Series E Seven Percent Senior Convertible Preferred Stock [Member] \| Redemption of Preferred Stock [Member]
Subsequent Event [Line Items]
Stock Redeemed or Called During Period, Shares \| shares			2,351,558
Preferred Stock, Dividend Rate, Percentage			7.00%
Preferred stock, par value \| $ / shares			$ 0.01
Stock Redeemed or Called During Period, Value			$ 3,400,000
Stock Redeemed or Called During Period, Value from Escrow			$ 2,500,000
Restricted Stock Private Placement [Member] \| Issuance of Equity [Member]
Subsequent Event [Line Items]
Stock Issued During Period, Shares, New Issues \| shares		833,333
Sale of Stock, Price Per Share \| $ / shares		$ 0.60
Stock Issued During Period, Value, New Issues		$ 500,000
Aspire Capital Purchase Agreement [Member]
Subsequent Event [Line Items]
Committment to Purchase Reporting Entity Common Stock, Value						$ 20,000,000
Aspire Capital Purchase Agreement [Member] \| Issuance of Equity [Member]
Subsequent Event [Line Items]
Common Stock, Shares, Issued \| shares								2,300,000
Stock Issued During Period, Value, New Issues								$ 1,500,000
Suzhou Erye Pharmaceuticals Company Ltd. [Member] \| Sale [Member]
Subsequent Event [Line Items]
Equity Method Investment, Ownership Percentage	51.00%
Divestiture, Purchase Price, Cash Portion	$ 12,280,000
Divestiture, Return of Common Stock, Shares \| shares	1,040,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period \| shares	1,170,000
Warrants Cancelled \| shares	640,000
Chief Executive Officer [Member] \| New Contract [Member]
Subsequent Event [Line Items]
Extension of Employment Agreement (in years)	2 years
Annual Base Salary	$ 495,000
Cash Bonus, Target Percent of Annual Base Salary For Progress Toward Stated Objectives	50.00%
Cash Bonus, Percent of Annual Base Salary For Extraordinary Performance	100.00%
Duration of COBRA Premiums Following Termination of Employment (in years)	1 year
Stock Options Vesting Period Following Termination of Employment (in months)	12 months
Stock Options Exercisable Period Following Termination of Employment (in years)	10 years
Duration Of COBRA Premiums Following Termination Of Employment With Cause (in years)	1 year